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CHAPTER I 
 
FUNCTIONAL EVOLUTION OF LOCAL SIGNALING DOMAINS IN 
METAZOAN CELL PHYSIOLOGY 
 
 
 
 Robert Hooke’s first microscopic glimpse into multicellular structure 
revealed a complex biological organization unimagined before the seventeenth 
century:  microscopic “cells” which he believed were the containers of “noble 
juices” (Hooke 1665).  Since Hooke’s original observation, the subcellular 
organization of vertebrate cells has been defined, revealing a complexity beyond 
simple compartmentalization (Twyman 1998).  While the development of the lipid 
cell membrane allowed retention of vital cellular components, it produced limited 
capabilities for communication, as well as decreased access to necessary 
substrates and the inefficient removal of waste.  While early forms of life, such as 
archaeabacteria, likely expressed simple transporters necessary for salt and 
water balance (Hille, Armstrong et al. 1999), the evolution of multicellular 
organisms necessitated the utilization of more complex transmembrane 
movement.  Specifically, the divergence of single-celled life forms into organisms 
composed of multiple cells types with specific functions required 
intercellular/intracellular communication, tissue synchronicity, homeostatic 
measures, and movement.  The evolution of specific ion channels, transporters, 
and pumps became primary mediators of these actions.  With the development of 
the submembranous cytoskeletal network, ion channels were provided with a 
platform for the micro-compartmentalization of ion channel-mediated activity.  
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This compartmentalization allowed for more rapid and efficient responses to 
stimuli, ultimately providing for the highly-choreographed release of hormones, 
excitation-coupling of the heart, and the firing of synapses.  While cells in 
vertebrate organisms express a distinct ‘toolbox’ of ion channels, it is the specific 
subcellular localization and regulation of these ion channels that contribute to the 
unique function of a particular cell type.  For example, the precise localization of 
voltage-gated sodium channels (Nav) to the cardiac Z-line (Maier, Westenbroek 
et al. 2004) provides for the initial upstroke necessary for the heartbeat 
(Nerbonne and Kass 2005), while these same channels at the nodes of Ranvier 
(Kazarinova-Noyes and Shrager 2002) and at the axon initial segments (Garrido, 
Fernandes et al. 2003) allow efficient and rapid propagation of electrical impulses 
that are necessary for neurotransmitter release, muscle movement, and memory 
(Vacher, Mohapatra et al. 2008).   
Recent work has demonstrated that mutations in ion channel genes which 
disrupt biophysical activity underlie a number of diseases, including a variety of 
cardiac arrhythmias (Lehnart, Ackerman et al. 2007), epilepsy (Steinlein 2008), 
and diabetes (Shield 2007).  The identification of numerous ‘channelopathies’ 
has been instrumental in defining the roles of various ion channels in physiology; 
however, most intriguing has been the observation that mutations which disrupt 
the assembly and regulation of ion channel complexes also result in disease.  
While the idea of ion channels consisting of only pore-forming subunits persisted 
in the early days of ion channel research, it is now recognized that most ion 
channels function within macromolecular complexes, comprised not only of the 
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pore-forming subunits, but also of associated auxiliary subunits, regulatory 
enzymes, and targeting proteins (Ashcroft 2006; Grueter, Abiria et al. 2006; 
Piggott, Bauman et al. 2008).   These associated protein partners play vital 
physiological roles that include feedback ion sensing, enzymatic activity, and the 
coordination, localization, and targeting of the ion channel assembly.  Rapsyn, for 
example, has been demonstrated to cluster the acetylcholine receptor (AChR) at 
specific excitatory synapse membranes (Chen, Qian et al. 2007), while the 
sulfonylurea receptor (SUR) regulatory subunit of the ATP-sensitive potassium 
channel (KATP) hydrolyzes adenosine triphosphate (ATP) and stimulates channel 
opening (Mikhailov, Campbell et al. 2005), in addition to conferring sensitivity to 
therapeutic drugs (Shindo, Yamada et al. 1998; Ashfield, Gribble et al. 1999).  
Likewise, MinK and MiRP proteins play critical roles in the modulation of the 
single channel conductance, gating, and pharmacology of distinct Kv channels 
(Deschenes and Tomaselli 2002; Pourrier, Schram et al. 2003; Lewis, 
McCrossan et al. 2004), while the activation/inactivation properties of many 
voltage-gated channels originate through association with protein kinases and 
protein phosphatases (Cai, Hernandez et al. 2005; Grueter, Abiria et al. 2006).  
Considering these necessary roles in ion channel regulation, it is easily 
appreciated that mutations in accessory subunits can also produce a variety of 
channelopathies.  For example, mutations in rapsyn have been associated with 
decreases in AChR density, resulting in myasthenic syndrome (Ohno, Engel et 
al. 2002); loss-of-function mutations in SUR1 causes congenital hyperinsulinemia 
by decreasing KATP channel activity (Ashcroft 2005), and loss-of-function 
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mutations in MinK and MiRP lead to potentially fatal long QT syndrome (Lu, 
Mahaut-Smith et al. 2003; Krumerman, Gao et al. 2004). 
 While much work has clearly defined the role of macromolecular 
complexes in the regulation of ion channel activity, recent advances in the study 
of channelopathies have also demonstrated that, in addition to proper channel 
biophysics and regulation by accessory proteins, functional ion channels and 
transporters require precise expression and localization to specific membrane 
domains within the cell.  A number of human diseases result from disruption of 
function due to abnormal channel targeting.  This has been most clearly defined 
in such conditions as cystic fibrosis (the cystic fibrosis transmembrane regulator 
protein, CFTR) (Puchelle, Gaillard et al. 1992), Timothy syndrome (voltage-gated 
calcium channel, Cav1.2) (Splawski, Timothy et al. 2005), Liddle syndrome 
(epithelial sodium channel, ENaC) (Hansson, Schild et al. 1995), and Bartter’s 
syndrome type II (inwardly rectifying potassium channel, Kir1.1) (Derst, Konrad et 
al. 1997).  From work on ion channel trafficking defects, it is now appreciated that 
ion channels and their accessory entourages are not isolated, functionally 
discrete islands in the sea of membrane lipids, but rather exist within spatially-
defined local membrane domains.  Within the past decade, a number of studies 
have associated dysfunction in the ankyrin family of adaptor polypeptides with 
ion channel dysfunction in the nervous system and heart (Mohler, Schott et al. 
2003; Ango, di Cristo et al. 2004; Mohler, Rivolta et al. 2004; Mohler, Splawski et 
al. 2004; Lowe, Palygin et al. 2008), specifically in regard to ion channel 
trafficking and retention at distinct membrane microdomains.  Dysfunction in the 
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cellular mechanisms involved in ion channel trafficking and retention at 
specialized membrane domains has emerged not only as a new focus in the field 
of channelopathy research, but has also become an exciting new discovery in the 
understanding of the complex mechanisms involved in the regulation of ion 
channel and transporter function and, ultimately, human physiology and 
pathology.   
 
Summary and Hypothesis 
 The myriad of diseases associated with impairment of channel function 
highlight the importance of ion channels in human physiology.  To date, over 60 
ion channel genes have been associated with human disease (Ashcroft 2006).  
However, new data from experiments in mice and primary cells demonstrate that 
the control and regulation of channel function by accessory proteins and the 
cytoskeleton are equally important for normal physiology.  In fact, dysfunction in 
accessory proteins has been linked with a host of human disorders.  These data 
illustrate that the evolution of multicellular organisms has required the 
establishment of local signaling domains not only for the regulation of ion channel 
biophysical properties, but also for efficient targeting.  Over the course of my 
thesis work, I have focused on understanding the role of protein 
compartmentalization and local signaling for vertebrate physiology.  Specifically, I 
have been most interested in understanding the link between ion channels in 
excitable cells, the underlying cytoskeleton, and vertebrate physiology.  Ankyrins, 
the family of membrane/cytoskeletal adaptors critical in the trafficking, retention, 
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and regulation of a number of ion channels, transporters, and pumps, have been 
identified as critical regulators of ion channel localization to membrane 
microdomains in excitable cells (reviewed in Chapter II) and are an underlying 
theme of my work. 
   In the first part of my thesis, I have focused on the role of ankyrin 
polypeptides for organizing ion channels on the exterior plasma membrane of 
excitable cells; namely, the Kir6.2 subunit of the KATP channel.  In the second part 
of my thesis, I have studied the role of ankyrin polypeptides and underlying 
cytoskeleton for compartmentalization of ion channels on the interior 
endoplasmic/sarcoplasmic reticulum (ER/SR) membrane, focusing on the inositol 
1,4,5-trisphosphate (InsP3) receptor.  Together, my data demonstrate a key role 
for ankyrin proteins in targeting and regulation of these two key ion channels at 
diverse membrane domains in multiple excitable cells, as well as a host of critical 
functions for normal excitable cell function. 
 The importance of KATP channel function in the process of insulin secretion 
has been established for over 20 years, fuelling the search for KATP channel 
mutations that result in diabetes (reviewed in Chapter III).  These studies have 
uncovered both heterozygous loss-of-function and gain-of-function mutations that 
underlie both congenital hyperinsulinemia and neonatal diabetes, respectively 
(Gloyn, Siddiqui et al. 2006).  In addition to the biophysical properties of ion 
channels, proper KATP channel localization is critical for function, with loss of KATP 
channel surface expression resulting in severe hyperinsulinemia (Partridge, 
Beech et al. 2001; Taschenberger, Mougey et al. 2002; Dunne, Cosgrove et al. 
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2004; Yan, Lin et al. 2004).  The KATP channel is also a critical mediator of 
ischemic preconditioning in the heart (Gumina, Pucar et al. 2003), neural 
protection from ischemic events (Heron-Milhavet, Xue-Jun et al. 2004), and 
critical to the regulation of cardiac action potential duration (Janse and Wit 1989; 
Wilde 1993).  Loss of KATP channel expression in cardiomyocytes and neurons 
also results in disease, further stressing the need to understand mechanisms 
underlying the targeting and retention of this ion channel to plasma membrane. 
 InsP3 receptors, on the other hand, reside on the membrane of the ER/SR 
and are critical players in the regulation of intracellular Ca2+ dynamics (reviewed 
in Chapter V).  Studies in cardiomyocytes, neurons, and beta cells have 
demonstrated the critical nature of these ion channels to excitation-contraction 
coupling, synaptic transmission, and insulin release.  Likewise, studies have 
demonstrated significant excitable cell dysfunction resulting from the loss of 
proper InsP3 receptor expression, localization, and regulation. 
 Using standard biochemical and electrophysiological techniques, I provide 
evidence in support of two major findings.  First, I present data suggesting that a 
novel ankyrin-B-dependent mechanism in the trafficking and metabolic regulation 
of Kir6.2 in excitable cells (presented in Chapter IV).  This interaction has not 
been observed before and represents evidence of a new binding partner for 
ankyrin-B.  Furthermore, the human Kir6.2 mutation, E322K, which is associated 
with human permanent neonatal diabetes mellitus (PNDM), results in a loss of 
ankyrin-B-dependent trafficking of Kir6.2 in transfected cells.  Moreover, loss of 
ankyrin-B association with Kir6.2 results in a decrease in KATP channel ATP 
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sensitivity.  The necessity of the ankyrin-B interaction for KATP channel sensitivity 
is a broad-reaching discovery.  Not only does it more fully elucidate the 
mechanisms involved in KATP channel regulation, but it also represents a novel 
role for ankyrin polypeptides in vivo; a role that supersedes the concept of 
ankyrins as simple targeting proteins.  Additionally, Kir6.2 association with 
ankyrin-B, a component of the actin/spectrin-based cytoskeleton, may provide 
the “missing link” between KATP channel regulation and the cytoskeleton.  Based 
upon these works, I propose that an ankyrin-B-dependent pathway is necessary 
for KATP channel localization and function in excitable cells.  Moreover, my work 
implicates a target for pharmacological exploitation in the treatment of insulin 
secretion disorders.   
 Second, I present evidence demonstrating the association of ankyrin-B 
with an N-terminal region of the InsP3 receptor, reversing a previous notion that 
this interaction occurred with a C-terminal domain of the InsP3 receptor 
(presented in Chapter VI).  The relevance of this finding resolves a long-standing 
debate regarding the validity and existence of in vivo ankyrin-B/InsP3 
interactions.  The importance of this clarification is essential in understanding the 
mechanisms underlying InsP3 receptor targeting in vivo and provides critical 
groundwork for elucidating the role of macromolecular signaling complexes at the 
ER/SR membrane.  Considering the importance of InsP3 regulation to excitable 
cell physiology, determination of the factors which modulate InsP3 receptor 
targeting and regulation would provide for a critical foundation to the 
development of pharmacological modification of InsP3 receptor activity.  This is of 
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particular interest with regard to decreased InsP3 receptor expression and 
aberrant regulation by InsP3. 
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CHAPTER II 
 
DYSFUNCTION OF ANKYRIN POLYPEPTIDES IN DISEASE 
 
Introduction 
Ankyrins are a family of cytosolic proteins whose functions include the 
organization, targeting, stabilization, and regulation of protein complexes.  
Specifically, ankyrins tether proteins to the actin/spectrin cytoskeleton, creating 
distinct functional membrane microdomains.  Canonical mammalian ankyrin 
polypeptides and alternative splice variants are expressed in both tissue-
dependent and developmentally-regulated manners, and arise from three 
separate genes, ANK1, ANK2, and ANK3.  ANK1, originally identified in 
erythrocytes, is on human chromosome 8p11 and encodes ankyrin-R (named for 
its “restricted” distribution in brain and muscle) (Lambert, Yu et al. 1990).  ANK2 
is on human chromosome 4q25-27 and encodes ankyrin-B, which demonstrates 
a ubiquitous expression pattern (hence, “broadly” expressed) (Tse, Menninger et 
al. 1991).  Finally, ANK3 is on human chromosome 10q21 and encodes ankyrin-
G (the largest of the ankyrin polypeptides, “giant” size) (Kapfhamer, Miller et al. 
1995).  Similar to ankyrin-B, ankyrin-G is ubiquitously-expressed.  Ankyrins are 
also found in other metazoan genomes including Caenorhabditis elegans (unc-
44) (Otsuka, Franco et al. 1995) and Drosophila (Dank1 and Dank2) (Dubreuil 
and Yu 1994; Bouley, Tian et al. 2000).  Due to the fact that ankyrin proteins 
have yet to be found in lower organisms such as Saccharomyces cerevisiae, 
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Arabidopsis thaliana, and Zea mays, there is a strong indication that ankyrin 
polypeptides have evolved with the development of multicellular organisms and 
represent an important molecular invention in the physiology of metazoan 
organisms. 
 
Domain Organization of Canonical Ankyrin Polypeptides 
 Canonical ankyrins have four distinct domains:  a membrane-binding 
domain (MBD) located at the N-terminus, a spectrin-binding domain (SBD), a 
death domain (DD), and a C-terminal domain (Figure 1).  Together with the death 
domain, the C-terminal domain forms a regulatory domain.  All four domains 
have been associated with distinct protein interactions (Figure 1).   
 A defining feature of ankyrin polypeptides is the membrane-binding 
domain, which is composed of 24 consecutive ANK repeats folded into four 
subdomains of six repeats each (Michaely and Bennett 1993) (Figure 2A).  An 
ANK repeat is an L-shaped 33 amino acid repeating motif recognized in over 400 
proteins in diverse organisms like viruses and humans with functions ranging 
from transcriptional activation to toxicity (Mosavi, Cammett et al. 2004).  
Specifically, the ANK repeat consists of pairs of antiparallel α-helices stacked 
side by side and connected by a series of intervening β-hairpin loops (Figure 2A, 
blowup).  It is hypothesized that loop tip residues mediate the specificity for 
protein interactions with ankyrins (Sedgwick and Smerdon 1999).  For example, 
the InsP3 receptor interacts with the β-hairpin loop tips located within ANK 
repeats 22-24 on ankyrin-B (Mohler, Davis et al. 2004), while the sodium-calcium 
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exchanger 1 (NCX1) interacts with the β-hairpin loop tips located within ANK 
repeats 16-18 of ankyrin-B (Cunha, Bhasin et al. 2007) (Figure 2B).  In the 
ankyrin family of polypeptides, the 24 ANK repeats stack into a solenoid structure 
(Figure 2A).  The role for ANK repeat-containing proteins in mediating protein-
protein interactions is well-documented, with the interesting characteristic that 
ANK proteins do not bind selectively to a particular class of protein target.  This 
allows for an unparalleled diversity in the unrelated proteins with which they 
interact (Figure 1).  Specifically, protein-protein interactions are achieved by 
highly-variable residues in the individual β-hairpin loop tips that are able to 
mediate charge-charge interactions between the ankyrins and their binding 
partners.  As expected, the ankyrin MBD has a number of documented cytosolic, 
membrane- and cytoskeleton-associated binding partners.  Specific binding 
partners that associate with ankyrins via the MBD include the Na+/K+ ATPase 
(NKA) (Nelson and Veshnock 1987; Morrow, Cianci et al. 1989; Thevananther, 
Kolli et al. 1998; Zhang, Devarajan et al. 1998; Mohler, Davis et al. 2005), the 
NCX1 (Li, Burke et al. 1993; Mohler, Davis et al. 2005; Cunha, Bhasin et al. 
2007), the anion exchanger (Bennett and Stenbuck 1979; Davis, Otto et al. 1991; 
Morgans and Kopito 1993; Jons and Drenckhahn 1998), voltage-gated Na+ 
channels (Nav) {Eber, 1996 #18;Srinivasan, 1988 #19;Malhotra, 2000 #20;Lowe, 
2008 #2}, the ammonium transporter (Lopez, Metral et al. 2005), Kv2.1 and Kv3.1 
channels (Rasmussen, Frokjaer-Jensen et al. 2007; Xu, Cao et al. 2007), 
Rhesus (Rh) antigen, and the H+/K+ ATPase (HKA) (Festy, Robert et al. 2001).  
Additionally, ankyrins interact with calcium-induced calcium-release channels of 
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the ER/SR via the MBD; namely, the InsP3 receptor (Bourguignon, Jin et al. 
1993; Joseph and Samanta 1993; Mohler, Davis et al. 2005; Kline, Cunha et al. 
2008).  Besides ion channels and transporters, the MBD also associates with 
members of three families of cell adhesion molecules:  CD44 polypeptides 
(Kalomiris and Bourguignon 1988), E-cadherin (Kizhatil, Davis et al. 2007), and 
L1CAMs (Davis and Bennett 1994; Dubreuil, MacVicar et al. 1996).  Additionally, 
ankyrins have cytosolic binding partners like tubulin (Bennett and Davis 1981; 
Davis and Bennett 1984; Davis, Otto et al. 1991) and clathrin (Michaely, Kamal et 
al. 1999).  Interestingly, the multivalent MBD is able to interact simultaneously 
with multiple partners, allowing a single ankyrin polypeptide to facilitate the 
formation of large protein complexes.  (Michaely and Bennett 1995; Michaely and 
Bennett 1995; Mohler, Davis et al. 2005).  In the erythrocyte, for example, 
ankyrin-R organizes two dimers of the anion exchanger as well as coupling of the 
anion exchanger with L1CAM (Michaely and Bennett 1995; Michaely and Bennett 
1995).  In cardiomyocytes, ankyrin-B forms a ternary complex of the NCX1, NKA, 
and the InsP3 receptor (Mohler, Davis et al. 2005).   
 The spectrin-binding domain of ankyrin polypeptides is responsible for 
interactions between ankyrin and the spectrin/actin cytoskeleton, specifically β-
spectrin, both in vitro and in vivo (Bennett and Stenbuck 1979; Davis and Bennett 
1984).    These observations led to the notion that the ankyrin/spectrin interaction 
existed solely to link the plasma membrane to the underlying cytoskeleton.  
However, more recent work has demonstrated that ankyrins mediate a much 
more substantial role in membrane domain biogenesis.  For  example,  hereditary 
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Figure 1.  Domain organization and binding partners of canonical ankyrins.   
Canonical ankyrins are organized into four domains:  an N-terminal membrane-
binding domain (blue), containing 24 ANK repeats; a spectrin-binding domain 
(red); a death domain (green); and a C-terminal domain (yellow).  Together with 
the C-terminal domain, the death domain forms a regulatory domain.  Ankyrins 
interact with a number of protein partners, representing a variety of protein 
families:  cell-adhesion molecules, ion channels, cellular transport molecules, 
cytoskeletal proteins, phosphatases, and heat shock proteins.  Adapted from 
Bennett and Healy, Trends Mol Med. 2008 14(1):28-36 (Bennett and Healy 
2008). 
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Figure 2.  ANK repeats mediate interaction with a number of protein 
binding partners.   
 
(A)  24 ANK repeats, divided into four subdomains of six repeats each, are folded 
into a solenoid structure.  Each ANK repeat consists of two α-helices separated 
by a β-hairpin loop (blowup).  Unique residues in the β-hairpin loops mediate 
specific associations with various proteins.  (B)  Distinct ANK repeats mediate 
interactions with binding partners.  The NCX1 associates with ankyrin-B via ANK 
repeats 16-18, while the InsP3 receptor associates with ankyrin-B via ANK 
repeats 22-24.  Reprinted with permission from Elsevier Ltd:  Trends in Mol Med 
14(1):28-36, copyright 2008 (Figure 2A) (Bennett and Healy 2008).  Reprinted 
with permission from the American Society for Biochemistry and Molecular 
Biology:  J Biol Chem 282(7):4875-83, copyright 2007 (Figure 2B) (Cunha, 
Bhasin, et al. 2007). 
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spherocytosis is associated with mutations in ankyrin-R that result in reduced 
spectrin levels (Bodine, Birkenmeier et al. 1984; Hanspal, Yoon et al. 1991; Eber, 
Gonzalez et al. 1996).  Additionally, there is a significant reduction in β4-spectrin 
levels following disruption of ankyrin-G in cerebellar neurons (Jenkins and 
Bennett 2001), specifically at the axon initial segment.  In the cardiomyocyte, it is 
the interaction between ankyrin-B and β2-spectrin that is necessary for the 
precise localization of β2-spectrin to the domain overlying the M-line (Mohler, 
Yoon et al. 2004).  New and exciting insights into the role of ankyrin polypeptides 
in membrane biogenesis emerged with the use of small interfering RNA (siRNA) 
to knock-down ankyrin-G expression in human bronchial epithelial cells.  
Reduction of ankyrin-G expression results not only in a reduction in β2-spectrin in 
the lateral membrane, but also in a complete loss of lateral membrane domains 
in general (Kizhatil and Bennett 2004), suggesting a necessary role for ankyrins 
not only in the targeting of ion channels to distinct domains, but also in the 
formation of entire membrane domains.  Similar studies have also demonstrated 
that ankyrin-G is a critical link between β2-spectrin and E-cadherin, a component 
of membranes necessary for lateral membrane formation during early 
development (Kizhatil, Davis et al. 2007).  Specifically, it has been demonstrated 
that ankyrin-G and β2-spectrin co-localize with E-cadherin in preimplantation 
mouse embryos, where knock-down of either ankyrin-G or β2-spectrin blocks 
accumulation of E-cadherin at sites of cell-cell contact (Kizhatil, Davis et al. 
2007).  In addition to spectrin, the spectrin-binding domain associates with the 
protein phosphatase, PP2A (Bhasin, Cunha et al. 2007).  Protein phosphatases 
 17
play critical roles in the regulation of a number of ion channels, implying an 
accessory role for ankyrin polypeptides in the regulation of these proteins via 
regulation of phosphorylation status.  Finally, an ankyrin-dependent pathway is 
required for sarcolemmal localization of dystrophin and β-dystroglycan, as well as 
critical for the protection of skeletal muscle against exercise-induced injury and 
the maintenance of the postnatal neuromuscular junction (Ayalon, Davis et al. 
2008).  Interestingly, an identified Becker muscular dystrophy mutation (D3335N) 
was found to reduce ankyrin binding, impairing sarcolemmal localization of 
dystrophin-Dp71 (Ayalon, Davis et al. 2008).    Moreover, ankyrin-B SBD and 
ankyrin-G SBD were also determined to bind dynactin-4, with loss of a subset of 
microtubules from sarcolemmal sites in ankyrin-B-depleted muscle (Ayalon, 
Davis et al. 2008).  
 The function of the 90 amino acid ankyrin death domain is currently 
unknown.  While previously published studies have demonstrated a role for death 
domains in the association of homotypic and heterotypic proteins (Xiao, Towb et 
al. 1999), there is no evidence to suggest a similar role for the death domain of 
ankyrins, since ankyrins do not homo-dimerize via their death domains with any 
significant affinity (Abdi, Mohler et al. 2006).  With other death domain-
expressing proteins, such as Fas, the death domain is hypothesized to be 
involved in the apoptotic pathway.  Interestingly, the death domain of ankyrin-G 
has been shown to interact with the death domain of FasL, promoting renal 
tubule cell death (Del Rio, Imam et al. 2004).  Moreover, overexpression of the 
ankyrin-G death domain results in Fas-mediated apoptosis of renal tubule cells, 
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suggesting that ankyrins may function in the regulation of apoptosis.  Human 
mutations in the death domain of ankyrin-B, which have been hypothesized to 
affect structure and/or stability of ankyrin polypeptides, have been identified.   
Such findings suggest that, while the death domain may be involved in the 
apoptotic events of certain cells types, it is very likely to be involved in pathways 
that are yet unknown. 
 The most divergent domain among ankyrins-R, -G, and –B is the C-
terminal (regulatory) domain, which has been shown to mediate the regulation 
of specific ankyrin functions in cells via intramolecular interactions.  More 
specifically, the C-terminal regulatory domain of ankyrin-B has been 
demonstrated to interact with the first ANK repeat within the ankyrin-B MBD, 
allowing rescue of normal localization of the InsP3 receptor in ankyrin-B+/- 
cardiomyocytes, even though this particular ANK repeat is not necessary for 
association with InsP3 receptor (this association is mediated by ANK repeats 22-
24; Figure 2B) (Abdi, Mohler et al. 2006).  In humans, loss-of-function mutations 
within the C-terminal regulatory domain of ankyrin-B have been associated with 
cardiac arrhythmias (“ankyrin-B syndrome”), providing compelling evidence for 
the critical role of this domain in ankyrin polypeptide function.  Studies have 
demonstrated that the C-terminal domain of ankyrin polypeptides is responsible 
for association with obscurin (Bagnato, Barone et al. 2003; Kontrogianni-
Konstantopoulos, Jones et al. 2003; Cunha and Mohler 2008) and the molecular 
co-chaperone human DnaJ homolog 1, Hdj1/Hsp40 (Mohler, Hoffman et al. 
2004).   
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Ankyrin Dysfunction and Abnormal Physiology 
Mutations in ankyrin-R are associated with spherocytosis and 
hemolytic anemia.  Ankyrins were originally identified in the erythrocyte 
membrane as a critical link between the actin/spectrin cytoskeleton and the 
integral membrane protein, the anion exchanger (Bennett and Stenbuck 1979).  
For years, ankyrins were considered simply scaffolding proteins, maintaining a 
direct connection between the plasma membrane and the underlying 
cytoskeleton.  The spectrin-based lattice of the erythrocyte links the actin 
cytoskeleton to integral membrane proteins like the anion exchanger.  Decreased 
expression and/or mutated forms of ankyrin-R have been associated with 
hemolytic anemia in humans (Eber, Gonzalez et al. 1996; Tse and Lux 1999).  A 
spontaneous and similar mutation in mice, nb/nb, was originally shown to result 
in a complete loss of 210 kD ankyrin-R expression in murine erythrocytes, 
neurons, and striated muscle (White, Birkenmeier et al. 1990), with the 
phenotype of severe anemia (Bodine, Birkenmeier et al. 1984) and Purkinje 
neuron degeneration (Peters, Birkenmeier et al. 1991).  Based on these findings, 
researchers were able to show that mutations of the ANK1 gene in humans were 
associated with decreased stability of spectrin and the anion exchanger, resulting 
in spherocytosis and anemia (Peters, Birkenmeier et al. 1991).  Interestingly, 
50% of Caucasian hereditary spherocytosis cases can be attributed to mutations 
in ankyrin-R (Delaunay 2002).  A much rarer form of anemia resulting from 
dysfunction in ankyrin-R is due to the absence of the Rh complex (Lopez, Metral 
et al. 2005).  Specifically, the Rh complex requires association with ankyrin-R for 
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stable expression in the erythrocyte (Lopez, Metral et al. 2005).  Loss of 
association results in features of spherocytosis:  decreased erythrocyte 
membrane stability and anemia (Lopez, Metral et al. 2005). 
 Ankyrin-G and the biogenesis of membranes in cardiomyocytes and 
neurons.  Ankyrin-G polypeptides are critical players in both the development 
and maintenance of membrane domains in neurons and cardiomyocytes.  In the 
brain, ankyrin-G co-localizes with both Nav channels and neurofascin (Kordeli, 
Lambert et al. 1995; Davis, Lambert et al. 1996).  A cerebellar-specific knock-out 
of ankyrin-G results in a phenotype indicative of cerebellar dysfunction:  
decreased locomotion, abnormal gait, and significant tremor (Zhou, Lambert et 
al. 1998).  Molecular work with this ankyrin-G mouse model has facilitated the 
determination of the role of ankyrin-G in the cerebellum:  Nav channel isoforms, 
neurofascin, and Kv2.1/Kv3.1 channels do not properly localize to specific 
membrane domains when ankyrin-G expression is disrupted (Zhou 1998; Jenkins  
2001; Pan 2006).  Specifically, loss of ankyrin-G results in reduced Nav channel 
localization to the neuromuscular junction as well as a loss of neurofascin and 
Kv2.1/Kv3.1 channel localization to the nodes of Ranvier and the Purkinje cell 
axon initial segments (Ango, di Cristo et al. 2004; Pan, Kao et al. 2006)  The 
results are abnormalities in cerebellar neuron action potentials, abnormal 
development of interneuron circuits, and reduced GABAergic synapse formation 
(Ango, di Cristo et al. 2004). 
 Likewise, a role for ankyrin-G in Nav1.5 trafficking to excitable domains of 
the heart has been established.  The importance of the Nav1.5/ankyrin-G 
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interaction was established with the identification and characterization of the 
human E1053K mutation of Nav1.5, which results in Brugada syndrome (Mohler, 
Rivolta et al. 2004).  Brugada syndrome is characterized as a cardiac arrhythmia 
associated with an increased risk of sudden cardiac death (Tester and Ackerman 
2008).  Specifically, the E1053K mutation of Nav1.5 blocks association with 
ankyrin-G, leading to accumulation of Nav1.5 E1053K in intracellular 
compartments and ultimately decreased expression of Nav1.5 at the intercalated 
disc and T-tubule membranes in ventricular cardiomyocytes (Mohler, Rivolta et 
al. 2004).  Interestingly, the cellular phenotype of E1053K is not solely due to 
retention of mis-folded intermediates in the ER/Golgi.  Using HEK293 cells, Lowe 
and colleagues showed that Nav1.5 E1053K was able to traffic efficiently to the 
membrane surface; however, these channels demonstrated a decreased 
threshold for voltage activation (Lowe, Palygin et al. 2008).  Therefore, ankyrin-G 
appears to play roles not only in the targeting of Nav1.5, but also in gating Nav1.5 
once at the cell membrane surface (Mohler, Rivolta et al. 2004). 
 Dysfunction in ankyrin-B and human arrhythmia.  Ankyrin-B is 
necessary for the establishment and maintenance of excitable membrane 
domains in the brain and striated muscle.  Anatomical examinations of mice that 
are homozygous for a null mutation in ankyrin-B have revealed a number of 
neurological defects:  hypoplasia of the corpus callosum and pyramidal tracts, 
dilation of the lateral ventricles, and degeneration of long axon tracts (Scotland, 
Zhou et al. 1998).  Since these defects are also associated with a loss of specific 
cell adhesion molecules throughout the brain, the role of ankyrin-B in normal 
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vertebrate nervous system function has been firmly established.  In addition to 
the neurological phenotype, ankyrin-B null neonatal mice also display thymic 
atrophy, pronounced kyphosis, winged scapula, occasional sarcomere 
disorganization, and elevations in plasma creatinine kinase levels, indicative of 
muscle damage (Tuvia, Buhusi et al. 1999). 
 Perhaps the greatest advances in ankyrin research focused on the link 
between ankyrin-B dysfunction and cardiac arrhythmia.  Neonatal 
cardiomyocytes isolated from both ankyrin-B null and ankyrin-B+/- mice have 
been reported to display abnormal Ca2+ dynamics, abnormal localization of 
ankyrin-associated proteins (i.e. InsP3 receptor, NCX1, and NKA), and cellular 
after-depolarizations (Mohler, Gramolini et al. 2002; Mohler, Schott et al. 2003).  
As a result, ankyrin-B+/- mice exhibit bradycardia, variable heart rate, stress- and 
exercise-induced polymorphic ventricular arrhythmia, and an increased incidence 
of sudden cardiac death (Mohler, Schott et al. 2003).  In 1995, Schott and 
colleagues identified a single ankyrin-B variant, E1425G, in a large French 
kindred that displayed an atypical cardiac arrhythmia:  bradycardia, abnormal 
heart rate, and stress-induced sudden cardiac death (Schott, Charpentier et al. 
1995; Mohler, Schott et al. 2003).  Using the molecular techniques that had 
established the basis of cardiac dysfunction in mice, Mohler et al. proved that the 
E1425G ankyrin-B variant was a loss-of-function mutation that resulted in cardiac 
arrhythmia and sudden cardiac death (Mohler, Schott et al. 2003).  Since the 
identification of the French E1425G probands, additional probands have been 
identified (T1404I, V1506G, T1552N, V1777M, R1788W, and E1813K) that 
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display cardiac arrhythmia, severe sinus bradycardia, idiopathic ventricular 
fibrillation, polyphasic T waves, and atrial fibrillation (Mohler, Splawski et al. 
2004; Mohler, Le Scouarnec et al. 2007; Le Scouarnec, Bhasin et al. 2008) .   
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CHAPTER III 
 
THE KATP CHANNEL:  THE METABOLIC SENSOR OF EXCITABLE CELLS  
 
 
 
Introduction 
 KATP channels play critical roles in many cellular functions by coupling cell 
metabolic status to electrical activity.  First discovered in cardiomyocytes (Noma 
1983), KATP channels have since been found in many other tissues and 
subcellular organelles, including pancreatic beta cells {Ashcroft, 1984 #61;Cook, 
1984 #62;Findlay, 1985 #63;Rorsman, 1985 #64}, skeletal muscle (Spruce, 
Standen et al. 1985), smooth muscle (Standen, Quayle et al. 1989), brain 
(Ashford, Sturgess et al. 1988), pituitary (Bernardi, De Weille et al. 1993), kidney 
(Hunter and Giebisch 1988), and in the mitochondria (Inoue, Nagase et al. 1991).  
By linking cellular metabolic state with membrane potential, KATP channels are 
able to regulate a number of cellular functions: hormone secretion, 
cytoprotection, vascular tone, and the excitability of both neurons and skeletal 
muscle (Figure 3).  Specifically, a reduction in metabolism causes a decrease in 
the ATP:ADP ratio, opening KATP channels and allowing K+ efflux, membrane 
hyperpolarization, and suppression of electrical activity.  Conversely, increased 
cellular metabolism causes a decrease in the ATP:ADP ratio and results in 
closure of the KATP channel, membrane depolarization, and the stimulation of cell 
electrical activity. 
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 Numerous studies using not only isolated cells and tissues, but also 
genetically-modified mice or patients with mutations in KATP channel genes, have 
demonstrated that KATP channels play a wide range of physiological roles (Seino 
and Miki 2004).  Their contribution to glucose homeostasis is well-documented 
with regard to KATP-dependent regulation of insulin secretion by beta cells 
(Ashcroft, Harrison et al. 1984), glucagon secretion from pancreatic alpha cells 
(Gopel, Kanno et al. 2000), somatostatin secretion from pancreatic delta cells 
(Gopel, Kanno et al. 2000), and glucagon-like peptide 1 (GLP-1) secretion from 
L-cells (Gribble, Williams et al. 2003).  Moreover, KATP channels in ventromedial 
hypothalamic neurons mediate the counter-regulatory response to glucose (Miki, 
Liss et al. 2001), while KATP channels in the arcuate nucleus are hypothesized to 
play a role in appetite regulation (Wang, Liu et al. 2004).  Interestingly, these 
glucose-sensing cell types express KATP channels that are open under resting 
conditions.  In other tissues, however, KATP channels are closed under 
physiological conditions and open only in response to ischemia, 
neurotransmitters, or hormonal stimulation (Figure 3).  For example, in cardiac 
muscle and central neurons, opening of KATP channels results in the reduction in 
electrical activity which protects against cardiac stress and seizures (Hernandez-
Sanchez, Basile et al. 2001; Yamada, Ji et al. 2001; Suzuki, Sasaki et al. 2002; 
Zingman, Hodgson et al. 2002; Heron-Milhavet, Xue-Jun et al. 2004).   Moreover, 
KATP channels are involved in the phenomenon of ischemic preconditioning in the 
heart (Gumina, Pucar et al. 2003) and in the regulation of vascular smooth 
muscle tone (Daut, Klieber et al. 1994; Chutkow, Pu et al. 2002; Miki, Suzuki et 
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al. 2002).  Additionally, KATP channels modulate electrical activity and synaptic 
neurotransmitter release in the hippocampus, substantia nigra, and the 
hypothalamus (Amoroso, Schmid-Antomarchi et al. 1990; Schmid-Antomarchi, 
Amoroso et al. 1990; Liss, Bruns et al. 1999; Zawar, Plant et al. 1999; 
Griesemer, Zawar et al. 2002; Avshalumov and Rice 2003; Wang, Liu et al. 
2004).  
 
Protein Architecture and Regulation of KATP Channel Function 
 The KATP channel is composed of two dissimilar subunits:  an inwardly 
rectifying K+ channel subunit (Kir6) and a regulatory subunit, SUR.  Both subunits 
are required to form a functional KATP channel and co-assemble in an obligate 4:4 
stoichiometry to form a hetero-octameric channel (Figure 4A) (Aguilar-Bryan and 
Bryan 1999).  Kir6, the pore-forming subunit, belongs to the inwardly rectifying 
potassium channel family.  Inward rectifiers are so named because of their 
preferential conduction of ions in an inward direction when compared to 
comparable positive and negative membrane potentials with symmetrical K+ 
distribution (Doupnik, Davidson et al. 1995).  Beta cells maintain a membrane 
potential that is positive to the potassium equilibrium potential (EK) so that K+ 
currents are mainly outward, and subject to physiological modulation by 
rectification (Doupnik, Davidson et al. 1995).  Two different Kir6 gene products 
have been described, Kir6.1 and Kir6.2, which share roughly 70% homology at 
the amino acid level (Inagaki, Gonoi et al. 1995; Inagaki, Tsuura et al. 1995; 
Sakura,  Ammala  et al.  1995).   While  KCNJ8  (encoding  Kir6.1)  is  located  at  
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Figure 3.  KATP channels in physiology.   
 
In the resting state, pancreatic beta cell KATP channels are open, keeping the 
membrane hyperpolarized.  Stimulation via increased plasma glucose results in 
KATP channel closure, membrane depolarization, and insulin secretion.  In 
contrast, KATP channels in cardiomyocytes and endothelial cells are closed in the 
resting state, opening in response to ischemia and vasodilators, respectively.  
The opening of the KATP channels in these cells results in membrane 
hyperpolarization and either a decrease in the action potential duration of the 
cardiomyocyte or vasodilatation in the endothelial cell.  Adapted from 
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chromosome position 12p11.23 (Inagaki, Inazawa et al. 1995), KCNJ11 
(encoding Kir6.2) is located at chromosome position 11p15.1 (Inagaki, Gonoi et 
al. 1995).  Both Kir6.1 and Kir6.2 are organized into two transmembrane helical 
domains, separated by a pore loop (P loop), with cytosolic N- and C-terminal 
domains (Figure 4B).   
 The regulatory subunit of the KATP channel, SUR, is a member of the ATP 
binding cassette (ABC) transporter superfamily, which also includes the CFTR 
and the multi-drug resistance proteins (MRPs).   SUR proteins were originally 
identified as components of the KATP channel as a result of the serendipitous 
observation that the administration of sulfonamides and sulfonylureas (SUs), 
such as tolbutamide and glibenclamide, resulted in hypoglycemia (Loubatieres 
1957).  Two closely related genes encoding the sulfonylurea receptors SUR1 
(ABCC8) and SUR2 (ABCC9) have been cloned and characterized.  The SUR1 
gene is located immediately upstream of Kir6.2 gene at chromosome 11p15.1 
(Thomas, Cote et al. 1995), while the SUR2 gene is located upstream of the 
Kir6.1 gene at chromosome position 12p12.1 (Chutkow, Simon et al. 1996).  
SUR2 has two major splice forms, SUR2A and SUR2B.  Similar to other 
members of the ABC subfamily C, SUR1 and SUR2 each contain two six-helix 
transmembrane domains (TMD1 and TMD2) (Figure 4C).  Additionally, SUR 
polypeptides have an N-terminal TMD0 domain consisting of five transmembrane 
helices (Figure 4C), unlike other members of the ABC superfamily.  SUR also 
contains two nucleotide binding folds:  NBF1, which is  between TMD1 and 
TMD2 and NBF2, which is after TMD2 (Figure 4C).  The various Kir6 and SUR 
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subunits are able to assemble in multiple variations to form KATP channels with 
different pharmacological (specifically, glibenclamide, a KATP channel closer and 
diazoxide, a KATP channel closer) and nucleotide sensitivities (Aguilar-Bryan, 
Nichols et al. 1995; Inagaki, Gonoi et al. 1995; Sakura, Ammala et al. 1995; 
Chutkow, Simon et al. 1996; Inagaki, Gonoi et al. 1996; Isomoto, Kondo et al. 
1996) (Table 1).  Comparison of the properties of cloned and native KATP 
channels demonstrates that the pancreatic beta cell KATP channel is composed of 
Kir6.2 and SUR1, the cardiac type is composed of Kir6.2 and SUR2A, and the 
smooth muscle type from Kir6.2 and SUR2B, although KATP channels composed 
of Kir6.1 and SUR2B have also been identified (Aguilar-Bryan, Nichols et al. 
1995; Inagaki, Gonoi et al. 1995; Sakura, Ammala et al. 1995; Chutkow, Simon 
et al. 1996; Inagaki, Gonoi et al. 1996; Isomoto, Kondo et al. 1996) (Table 1).  
Kir6.2 and SUR1 are also co-expressed in various brain neurons and are 
hypothesized to form KATP channels isolated from these tissues (Karschin, Ecke 
et al. 1997). 
 KATP channels are regulated by numerous cytosolic factors.  Perhaps the 
most studied factors responsible for KATP channel regulation are adenosine 
nucleotides, which interact with two different sites on the channel, one inhibitory 
and the other stimulatory.  Increased entry and glycolysis of glucose results in 
changes in cytosolic concentrations of adenosine nucleotides such as ATP and 
adenosine diphosphate (ADP).  Both sites can be distinguished experimentally, 
considering that nucleotide binding to the stimulatory site requires Mg2+ (Nichols, 
Shyng et al. 1996).  Therefore, in the absence of Mg2+, only the inhibitory effect is  
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Figure 4.  Stoichiometry and domain organization of the KATP channel. 
 
(A)  The KATP channel is 4:4 hetero-octamer of pore-forming Kir6.2 subunits 
(green) and regulatory SUR subunits (blue).  (B)  Kir6.2 is organized into N-
terminal and C-terminal cytoplasmic domains and two transmembrane domains 
(signified in green) with an intervening P-loop.  (C)  SUR isoforms are comprised 
of 17 transmembrane domains, organized into three subdomains:  TMD0 (light 
blue; comprised of five transmembrane domains) and TMD1 and TMD2 (dark 
blue; both of which are comprised of six transmembrane domains).  Between 
TMD1 and TMD2 is the first of two NBFs, NBF1).  The second NBF, NBF2, is 
located after TMD2. 
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Table 1.  Combinations of Kir6 and SUR subunits in distinct tissues with 
relative sensitivities to ATP, sulfonylureas, and potassium channel 
openers. 
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observed.  Within the cell, however, Mg2+ is always present; therefore, channel 
activity must be determined by the ratio of ATP to ADP.  Studies have 
demonstrated that the binding site for channel inhibition by ATP resides on Kir6.2 
(Craig, Ashcroft et al. 2008), where binding of ATP has been shown to stabilize 
the closed state of the channel (Enkvetchakul and Nichols 2003).  On the other 
hand, in the presence of Mg2+, both MgATP and MgADP stimulate KATP channel 
activity via binding to the NBFs of SUR (Nichols, Shyng et al. 1996).  It is 
hypothesized that the balance between activation by the Kir6.2 subunit and 
inhibition by the SUR subunit in response to nucleotide binding determines the 
overall level of KATP channel activity.  
 
KATP Channel Regulation by the Cytoskeleton 
 Several elegant experiments have demonstrated a clear role for the actin-
based cytoskeleton in the regulation of KATP channel function (Brady, Alekseev et 
al. 1996; Furukawa, Yamane et al. 1996; Terzic and Kurachi 1996; Yokoshiki, 
Katsube et al. 1997).  For well over a decade, the KATP field has struggled to 
identify the “missing link” between the KATP channel and the cytoskeleton (Brady, 
Alekseev et al. 1996; Furukawa, Yamane et al. 1996; Terzic and Kurachi 1996; 
Yokoshiki, Katsube et al. 1997).  The presence of this critical “adapter” was first 
proposed by Terzic and colleagues (Terzic and Kurachi 1996) in the mid 1990’s, 
based on a series of experiments that demonstrated a striking stimulatory effect 
of actin filament disrupting agents on KATP channel opening (Brady, Alekseev et 
al. 1996), and reproduced by multiple groups.  Specifically, it was observed that 
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disruption of actin cytoskeleton using cytochalasin (or DNAase I) resulted in the 
activation of KATP channels in excitable cells (Brady, Alekseev et al. 1996; 
Furukawa, Yamane et al. 1996; Terzic and Kurachi 1996; Yokoshiki, Katsube et 
al. 1997).  Moreover, work from multiple groups demonstrated that disruption of 
the actin cytoskeleton resulted in a gain-of-function phenotype by reducing the 
sensitivity of KATP channels for ATP-dependent channel closure (Terzic and 
Kurachi 1996).  Additionally, cytoskeletal disruption resulted in reduced KATP 
channel sensitivity to closure by SU compounds (Terzic and Kurachi 1996).   
Thus, the coupled impairment in SU and ATP sensitivities indicates a common 
transduction pathway of inhibitory gating signals that work in a manner 
dependent on the integrity of the cytoskeletal network.  Based on the role of 
ankyrins and spectrin in other cell types, it is possible that the ankyrin/spectrin 
cytoskeletal complex may perform this role for the KATP channel.  
 
 
KATP Channel Trafficking 
 Considering that changes in channel copy number at the cell plasma 
membrane can significantly alter the electrical properties of a cell, mechanisms to 
control channel numbers at the plasma membrane are critical for cellular function 
(Ma and Jan 2002).  Uncontrolled KATP channel activity, for example, can have 
deleterious results.  Excessive KATP channel opening in the heart leads to a 
shortening of the action potential duration and a loss of cellular K+, which can 
result in arrhythmia (Janse and Wit 1989; Wilde 1993), while excessive KATP 
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channel activity in the brain produces hyperpolarization and reduced excitability, 
which results in neuron silencing (Yamada and Inagaki 2002).   Therefore, 
regulation of KATP channel plasma membrane expression under stress is 
necessary to confer neuronal and cardiac protection without incurring serious 
damage. As such, Jan and colleagues demonstrated a protein-kinase C-
mediated pathway for KATP channel downregulation via dynamin-dependent 
endocytosis.  The resulting downregulation acts as a brake to lessen the 
shortening of the action potential duration in cardiomyocytes, as well as the rapid 
decline of excitability in neurons (Hu, Huang et al. 2003).   
 Unfortunately, there are little data which fully address the cellular events 
necessary to regulate KATP channel targeting and retention.  The observation that 
neither SUR1 nor Kir6.2 subunits are capable of channel activity when expressed 
alone (Aguilar-Bryan, Nichols et al. 1995; Inagaki, Gonoi et al. 1995; Tucker, 
Gribble et al. 1997) triggered a number of studies on KATP channel formation 
(John, Monck et al. 1998; Makhina and Nichols 1998; Zerangue, Schwappach et 
al. 1999).  Tucker et al. demonstrated that Kir6.2 can be forced to express 
channel activity independently of SUR1 by truncation of the distal 26-36 residues 
of Kir6.2 (Tucker, Gribble et al. 1997).  Using this truncated construct in 
combination with a sensitive assay to detect surface expression of KATP channels 
in the Xenopus oocyte model, an ER localization signal (RKR) was mapped in 
both the Kir6.2 and SUR1 proteins (Zerangue, Schwappach et al. 1999).  In KATP 
channels, it is believed that assembly of Kir6.2 and SUR1 subunits in an obligate 
4:4 stoichiometry masks the ER localization signals and allows the fully 
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assembled KATP channel to exit the ER (Zerangue, Schwappach et al. 1999).  
However, it has also been demonstrated that Kir6.2 and SUR1 are able to traffic 
independently of each other, suggesting that other mechanisms may be present 
that are necessary for KATP assembly and trafficking (Makhina and Nichols 1998).  
More recently, the coatamer I (COPI) vesicle coat complex has been shown to 
specifically recognize the RKR signal present in the Kir6.2 distal tail (Yuan, 
Michelsen et al. 2003).  Additionally, it was revealed that 14-3-3 proteins can also 
recognize this signal, dependent upon how many copies are in close proximity.  
Using reporter membrane proteins, a model which implicates dimeric 14-3-3 
proteins as sensors for multimeric assembly was proposed (Yuan, Michelsen et 
al. 2003).  Specifically, this model hypothesizes that the COPI vesicle coat 
recognizes the RKR signal exposed by unassembled subunits or partially 
assembled complexes, resulting in the retrieval of these proteins to the ER.  
Once the peptide trafficking signals come into close proximity, 14-3-3 proteins 
recognize them with high avidity and shield them from recognition by the COPI 
coat.  It remains to be tested whether 14-3-3 proteins are involved in the 
assembly-dependent trafficking of the KATP channels.  Nevertheless, these 
studies provide important information that will be useful in any research 
addressing the role of specific proteins (chaperones, adaptor proteins, or 
regulatory molecules) in the assembly and trafficking of KATP channels.   
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Beta Cell KATP Channels and Glucose-stimulated Insulin Secretion 
 The primary physiological function of the beta cell is to sense changes in 
circulating glucose levels and to respond with an appropriate insulin secretory 
response.  The significance of this function is of profound importance to health 
because its failure disrupts normal blood glucose homeostasis and results in 
insulin secretory abnormalities such as diabetes mellitus and hyperinsulinemia 
(Gloyn, Siddiqui et al. 2006).  Although KATP channels were initially identified in 
the heart (Noma 1983), their physiological importance was first established in the 
pancreatic beta cell.  In the beta cell, the KATP channel couples membrane 
excitability with glucose-stimulated insulin secretion (Ashcroft and Rorsman 
1990).  According to this paradigm, during conditions of low plasma glucose 
(fasting conditions), KATP channels are the dominant beta cell membrane 
conductance, maintaining the cell in a hyperpolarized state (approximately -70 
mV) (Figure 5A).  Conversely, following the ingestion of a meal, glucose enters 
the beta cell and is rapidly converted to ATP.  The increased production of ATP 
gives rise to an increase in the cytoplasmic [ATP]/[ADP] ratio, ATP-dependent 
closure of the KATP channel, membrane depolarization, and voltage-dependent 
Ca2+ entry via L-type calcium channels.  Calcium influx, in turn, triggers the 
mobilization, fusion, and exocytosis of insulin granules (Figure 5B).  The rise in 
circulating insulin, in turn, results in increased glucose uptake by the peripheral 
tissues and a compensatory drop in blood glucose.    
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Figure 5.  The beta cell KATP channel couples glucose metabolism to insulin 
secretion.   
 
(A)  Under conditions of low plasma glucose, the KATP channel is open, keeping 
the beta cell membrane hyperpolarized, resulting in negligible insulin secretion.  
(B)  Increased cellular metabolism, in response to increased plasma glucose 
levels, results in an increase in intracellular ATP, ATP-dependent closure of the 
KATP channel, membrane depolarization, and the activation of L-type calcium 
channels.  The increase in intracellular Ca2+ triggers insulin granule mobilization, 
fusion, and exocytosis.  Adapted from Ashcroft, J Clin Invest.  2005 115(8):2047-
58 (Ashcroft 2005). 
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 KATP channels also serve as the main target for pharmacological regulation 
of insulin secretion.  Sulfonylurea drugs (SUs; such as glibenclamide and 
gliclazide), which are widely used to treat type 2 diabetes, stimulate insulin 
secretion by closing KATP channels (Gribble and Reimann 2003). Specifically, 
SUs bind to unique areas on the regulatory SUR subunits, causing the KATP 
channel to close.  Thus, SUs by-pass beta cell metabolism, but stimulate the 
same intracellular events as glucose.   In contrast, a structurally diverse group of 
drugs, the K+ channel openers (KCOs), open KATP channels, thereby inhibiting 
insulin secretion (Ashcroft and Gribble 2000). 
 
KATP Channel Genes and Insulin Secretion Disorders 
 Electrical activity of the beta cell membrane is essential for insulin 
secretion.  Specifically, this electrical activity is in the form of Ca2+-dependent 
action potentials:  no insulin secretion in the absence of Ca2+, with the extent of 
insulin secretion correlated directly to that of electrical activity (Henquin 2000).  
The KATP channel not only initiates electrical activity, but also regulates its extent 
at stimulatory glucose concentrations.  This is due to the fact that the KATP 
channel controls the resting potential of the pancreatic beta cell (Tarasov, 
Welters et al. 2006).  Considering their critical role in regulating electrical 
excitability in a number of cell types, it is apparent that disruption of KATP channel 
function can lead to disease.  Mutations in KATP channel genes have been 
associated with neonatal diabetes (Gloyn, Pearson et al. 2004), hyperinsulinemia 
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(Dunne, Cosgrove et al. 2004), and dilated cardiomyopathy (Bienengraeber, 
Olson et al. 2004).   
 Alterations in metabolic signal, in the responsiveness of the KATP channel 
to metabolites, or in the number of active KATP channels at the beta cell 
membrane surface can lead to altered release of insulin.  Specifically, increased 
metabolic flux, increased sensitivity to inhibitory nucleotides, or reduced density 
of KATP channels result in low KATP activity and, therefore, hyperinsulinemia (a 
loss-of-function phenotype).  On the other hand, decreased metabolic flux, 
decreased sensitivity to inhibitory nucleotides, or increased density of KATP 
channels results in high KATP channel activity and hypoinsulinemia (a gain-of-
function phenotype).  These principles underlie the development of congenital 
hyperinsulinemia of infancy (CHI) and neonatal diabetes mellitus (NDM), 
respectively (Figure 6). 
 Congenital hyperinsulinemia of infancy.  CHI is characterized by 
continuous and unregulated insulin secretion in the presence of severe 
hypoglycemia (Dunne, Cosgrove et al. 2004).  Without treatment, persistent 
hypoglycemia may result in irreversible brain damage.  Loss-of-function 
mutations in SUR1 (ABCC8) are the most common cause of CHI, accounting for 
nearly 50% of diagnosed cases (Glaser, Thornton et al. 2000; Dunne, Cosgrove 
et al. 2004).  There are over 100 CHI mutations in SUR1 (Dunne, Cosgrove et al. 
2004; Gloyn, Siddiqui et al. 2006), comprising two functional classes:  those that 
result in no channel protein present at the surface membrane (class I) and those 
where the channel, though present at the surface membrane, is always closed 
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(class II).  Mechanistically, class I mutations are described by loss of KATP 
channels in the plasma membrane, resulting from impaired SUR1 synthesis, 
abnormal SUR1 maturation, defective channel assembly, or dysfunctional 
surface membrane trafficking (Partridge, Beech et al. 2001; Taschenberger, 
Mougey et al. 2002; Dunne, Cosgrove et al. 2004; Yan, Lin et al. 2004) (Figure 
6B).  On the other hand, class II mutations result in an inability of MgADP to 
stimulate channel activity {Dunne, 2004 #100;Huopio, 2000 #104;Nichols, 1996 
#105}.  As such, ATP inhibition becomes dominant and the KATP channel is 
closed even at low glucose concentrations.  There is no genotype-phenotype 
correlation regarding KATP channel mutations with differing degrees of severity 
presenting in different individuals. 
 Mutations in Kir6.2 (KCNJ11) resulting in CHI are much rarer than SUR1.  
Similarly, Kir6.2 mutations result in the reduction/abolishment of KATP channel 
activity at the plasma membrane.  Because the KATP channel maintains the beta 
cell membrane potential, decreased channel activity produces a persistent 
membrane depolarization, resulting in continuous insulin secretion (Figure 6B) 
 Often CHI is associated with neurological abnormalities; however, it is 
difficult to ascertain whether such abnormalities result from hypoglycemia or are 
a direct consequence of the mutation per se.  Since KATP channels are normally 
closed at rest in many extrapancreatic tissues, it is hypothesized that loss-of-
function mutations have little effect outside of the beta cell.  The majority of 
individuals with CHI undergo a sub-total pancreatectomy as infants to control the 
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hyperinsulinemia; whereas, non-surgically treated patients sometimes progress 
to glucose intolerance or diabetes (Huopio, Otonkoski et al. 2003). 
 Neonatal Diabetes Mellitus.  Neonatal diabetes mellitus is characterized 
by hyperglycemia developing within the first six months of life with lifelong 
dependence upon insulin therapy (Edghill, Gloyn et al. 2004).  Transgenic mice 
with overactive KATP channels are diabetic from birth, suggesting that overactive 
KATP channels may be a cause of neonatal diabetes (Koster, Marshall et al. 
2000).  Such gain-of-function (activating) mutations would make the channel 
more open under conditions of high plasma glucose (Figure 6A).  This would 
result, hypothetically, in plasma membrane hyperpolarization and impairment of 
insulin secretion, resulting in neonatal diabetes (Figure 6A).  In 2004, the first 
mutations in Kir6.2 were reported, confirming previous hypotheses regarding the 
role of Kir6.2 dysfunction in the development of neonatal diabetes (Gloyn, 
Pearson et al. 2004).  To date, over 30 mutations in Kir6.2 are associated with 
neonatal diabetes (Hattersley and Ashcroft 2005; Flanagan, Patch et al. 2007).  
An in-depth analysis of these mutations revealed that neonatal diabetes due to 
mutations in the KCNJ11 gene represent a rare disease, affecting approximately 
1 in 200,000 live births (Edghill, Gloyn et al. 2004).  Furthermore, all Kir6.2 
mutations identified to date are heterozygous (Babenko, Polak et al. 2006; Ellard, 
Flanagan et al. 2007) and gain-of-function (Proks, Antcliff et al. 2004; Ashcroft 
2005; Hattersley and Ashcroft 2005; Proks, Girard et al. 2005; Girard, 
Shimomura et al. 2006; Proks, Girard et al. 2006; Shimomura, Girard et al. 2006; 
Masia, Koster et al. 2007; Shimomura, Horster et al. 2007).   
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 Neonatal diabetes patients with KATP channel mutations can be 
categorized into four groups, depending on severity.  One group has transient 
neonatal diabetes mellitus (TNDM) which remits and enables the discontinuance 
of insulin treatment.  Another group has permanent neonatal diabetes mellitus 
(PNDM) which does not remit and requires insulin therapy throughout life.  
PNDM and TNDM result from the most common mutations.  Some mutations, 
however, cause more severe phenotypes and are categorized in one of the final 
two groups.  The most severe phenotype is known as DEND syndrome 
(developmental delay, epilepsy, and neonatal diabetes) (Hattersley and Ashcroft 
2005).  Some patients, however, have intermediate DEND (iDEND) which 
manifests with various degrees of motor weakness and also delays in social 
activities (Hattersley and Ashcroft 2005).  The severity of disease is dictated by 
both the tetrameric organization of the channel as well as the functional 
consequence of the mutation (Ashcroft 2005) (Figure 7).  Mutations that disrupt 
ATP binding usually cause only neonatal diabetes.  This is because binding of 
just one ATP is sufficient to shut the pore (Markworth, Schwanstecher et al. 
2000).  Because mutant and wild type subunits associate randomly, in the 
heterozygous state only one-sixteenth of the channels will have a severe 
reduction in ATP sensitivity (Figure 7).  In contrast, the more severe DEND 
mutations usually result in a stabilization of the intrinsic open state of the 
channel, reducing ATP block indirectly (Ashcroft and Rorsman 2004).  Because 
each subunit contributes to gating of the tetrameric pore, heteromeric channels 
containing both wild type and mutant subunits will be affected (that is 15 out of 16 
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channels in heterozygotes; Figure 7).  Consequently, DEND mutations produce a 
greater reduction in ATP sensitivity and a more severe disease phenotype.  
Thus, Kir6.2 mutations illustrate how the tetrameric nature of the KATP channel 
pore can result in a spectrum of phenotypes. 
 
Mouse Models of KATP Channel Mutations Recapitulate Hyperinsulinemia or 
Neonatal Diabetes  
 
 Gain-of-function KATP channel mutations associated with severe neonatal 
diabetes in mice (Koster, Marshall et al. 2000) were characterized before it was 
shown in humans (Gloyn, Pearson et al. 2004).  Because the mutations could be 
targeted to the beta cell, extrapancreatic phenotypes (similar to those seen in 
human patients) were absent.  While no change in insulin content or beta cell 
number was observed, serum insulin levels were critically low, due to the 
reduced ATP sensitivity of the mutant KATP channel introduced into the transgenic 
mice (Koster, Marshall et al. 2000).  Moreover, when this mutant transgene was 
introduced to the heart, there were no obvious cardiac symptoms (Koster, Knopp 
et al. 2001), as was seen in patients with gain-of-function KATP channel mutations 
(Gloyn, Pearson et al. 2004; Ashcroft 2005).  Interestingly, mice that expressed 
the mutant transgene at lower levels demonstrated impaired glucose tolerance 
rather than diabetes (Koster, Remedi et al. 2006).  Therefore, similar to humans, 
mice exhibit a spectrum of disease phenotypes which correlate to the extent of 
KATP channel activity.  A study by Nichols et al. demonstrated that mice 
heterozygous for Kir6.2 in beta cells demonstrated hyperinsulinemia, in contrast 
to the prediction that a reduction in Kir6.2 expression would result in a decrease 
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Figure 6.  Mutations in KATP channel genes result in abnormal insulin 
release.   
 
(A)  Gain-of-function mutations in Kir6.2 result in a KATP channel that is 
insensitive to ATP; therefore, KATP channels remain open, even in the presence 
of high intracellular ATP.  The result is hypoinsulinemia and neonatal diabetes.  
(B)  In contrast, loss-of-function mutations in either Kir6.2 or SUR1 result in no 
functional KATP channels at the plasma membrane.  The result is continual beta 
cell membrane depolarization and insulin release.  This produces congenital 
hyperinsulinemia.  Adapted from Ashcroft, J Clin Invest.  2005 115(8):2047-58 
(Ashcroft 2005). 
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Figure 7.  Severity of disease is dictated by both the tetrameric nature of 
Kir6.2 and the functional consequence of the mutation.   
 
Mutations that disrupt Kir6.2 ATP binding usually cause only neonatal diabetes.  
This is because binding of just one ATP to the channel is sufficient to close the 
channel.  Because mutant and wild type subunits associate randomly, in the 
heterozygous state, only one-sixteenth of the channels will have strongly reduced 
ATP sensitivity (circled).  In contrast, the more severe DEND mutations usually 
stabilize the intrinsic open state of the channel, reducing ATP block indirectly.  
Because each subunit contributes to gating of the tetrameric pore, heteromeric 
channels containing both wild type and mutant subunits will be affected (15 out of 
16 channels).  Consequently, DEND mutations produce a greater reduction in 
ATP sensitivity and more severe disease.  Adapted from Ashcroft, Nature.  2006 
440(7083):440-7 (Ashcroft 2006). 
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in insulin secretion (Remedi, Rocheleau et al. 2006).  From this study, Nichols 
proposed an inverse-U model of insulin secretion versus islet excitability.   
According to Nichols’ model, insulin secretion by wild type islets represents the 
normal secretory responsiveness to glucose.  Heterozygous Kir6.2 islets 
demonstrate hyperinsulinemia, placing this mouse model of decreased channel 
activity on the “ascending” limb of the curve.  Finally, Kir6.2 null islets 
demonstrate maximally enhanced excitability, demonstrating an undersecretory 
phenotype, placing them on the “descending” limb of the inverse-U curve 
(Remedi, Rocheleau et al. 2006).  
 Mice lacking functional KATP channels (loss-of-function) had beta cells that 
were depolarized and had elevated basal [Ca2+]i, as predicted (Miki, Tashiro et al. 
1997; Miki, Nagashima et al. 1998; Seghers, Nakazaki et al. 2000; Koster, 
Remedi et al. 2002).  As such, glucose-stimulated insulin secretion from these 
isolated islets was absent, confirming the necessity of KATP channels for insulin 
secretion.  Surprisingly, animals expressing a functionally inactivated dominant-
negative Kir6.2 mutation (Kir6.2G132S) demonstrated hypoglycemia and 
hyperinsulinemia as neonates that developed into hyperglycemia due to 
substantial beta cell loss as adults (Miki, Tashiro et al. 1997).  In similar 
experiments, when either Kir6.2 or SUR1 were genetically deleted, adult mice 
had reduced insulin secretion, yet were normoglycemic (Miki, Nagashima et al. 
1998; Seghers, Nakazaki et al. 2000).  Even more surprising was that mice 
expressing a different dominant-negative mutation in Kir6.2 exhibited 
hyperinsulinemia as adults and showed no significant beta cell loss (Koster, 
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Remedi et al. 2002).  Based on these studies, it was proposed that this 
unexpected phenotype was produced by KATP channel activity that was only 
partially suppressed (due to the fact that 30% of the beta cells were unaffected).   
 
 
Concluding Remarks 
 In the twenty years since their discovery, work with animal models and 
humans expressing KATP channel mutations have clearly defined a critical role for 
KATP channels in physiology.  While some pathways and mechanisms have been 
identified with regard to KATP channel activity, there are significant gaps in our 
knowledge of the molecular mechanisms underlying channel trafficking, 
regulation, and pharmacological action.  For example, the SU family of anti-
diabetic drugs have been used since the 1940s to treat diabetes; however, the 
mechanism of SU activity has not been clearly defined.  Likewise, the generation 
of conflicting data regarding the trafficking and regulation of KATP channel activity 
have made understanding the role of KATP channels in physiology confusing.  
Considering their vital role in human physiology and as targets of pharmaceutical 
action, a more complete understanding of KATP channel activity is necessary to 
provide the framework for future work regarding KATP channel regulation and 
pharmacological modulation. 
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CHAPTER IV 
 
NOVEL ROLES OF ANKYRIN FOR KATP CHANNEL TARGETING AND 
METABOLIC REGULATION 
 
 
Introduction 
 The critical function of ankyrin-B in excitable cells, namely the 
cardiomyocyte, has illuminated the necessary role of ankyrin polypeptides in 
human physiology.  Specifically, ankyrin-B has been demonstrated to participate 
in the trafficking, retention, and regulation of ion channels to distinct membrane 
microdomains.  The loss of ankyrin-B expression in the cardiomyocyte, for 
example, results in a significant decrease in the expression and localization of 
NKA, NCX1, and InsP3 receptor to the transverse tubule, resulting in abnormal 
Ca2+ dynamics and after-depolarizations.  The consequence is cardiac 
arrhythmia and an increased risk for sudden cardiac death (Mohler, Gramolini et 
al. 2002; Mohler, Schott et al. 2003).  Likewise, loss of association of ankyrin-G 
with Nav1.5 has been determined to be the underlying molecular mechanism of 
Brugada syndrome, a deadly heart arrhythmia associated with a right bundle 
branch block (Tester and Ackerman 2008). Ankyrin-G has also been 
characterized as a necessary component of the axon initial segment and the 
nodes of Ranvier.  In these specialized domains, ankyrin-G functions to target 
and retain Nav and Kv channels that are necessary for the generation of action 
potentials and propagation of neuronal electrical impulses (Kordeli, Lambert et al. 
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1995; Davis, Lambert et al. 1996).  As such, defects in ankyrin-G neuronal 
pathways of ion channel targeting result in decreased locomotion, abnormal gait 
and tremor (Zhou, Lambert et al. 1998).  
  Although ankyrin-B is a ubiquitously-expressed polypeptide, expression in 
the pancreas has only recently been reported (Mohler, Healy et al. 2007).  
Specifically, ankyrin-B expression is highly localized to the pancreatic islet, with 
the pancreatic beta cell expressing the highest levels of ankyrin-B (Mohler, Healy 
et al. 2007).  Like the cardiomyocyte, the electrophysiology of the pancreatic beta 
cell presides over its function; namely, insulin secretion.  A number of ion 
channels, transporters, and pumps are necessary for the maintenance of beta 
cell membrane potential.  Additionally, many known ankyrin-B binding partners 
are expressed in the pancreatic beta cells.  Based on previous studies describing 
the roles of ankyrin polypeptides in ion channel trafficking and function in 
excitable cells, I evaluated the role of ankyrin-B in beta cell physiology.  Initial 
observations that ankyrin-B and Kir6.2 co-immunoprecipitate in both pancreatic 
and heart lysate led to the exciting in vitro observation that ankyrin-B associates 
with a conserved C-terminal motif in the pore-forming subunit of the KATP 
channel, Kir6.2.  This interaction is specific to Kir6.2, considering that ankyrin-B 
is unable to co-immunoprecipitate with a similar isoform, Kir6.1.  In addition, I 
was able to refine the ankyrin-B-binding domain of Kir6.2 to an eight amino acid 
motif that is both necessary and sufficient for interaction with ankyrin-B.  Further 
analysis revealed that a known human mutation in Kir6.2 associated with PNDM, 
E322K, is located within this ankyrin-B-binding domain.  This mutation results in 
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loss of the ankyrin-B/Kir6.2 interaction in vitro and a loss of Kir6.2 trafficking in 
vivo.  Biophysical analysis also revealed that E322K results in a decrease in the 
ATP sensitivity of the KATP channel.  Finally, preliminary data using a competing 
peptide imply that association with ankyrin-B is necessary for KATP channel 
metabolic regulation in vivo.  These data suggest a novel role for ankyrin-B in the 
pancreatic beta cell; namely, the trafficking and regulation of Kir6.2 in excitable 
tissues. 
 
Methods and Experimental Approach 
 Animals.  Mice used in this study were six month old wild type and 
ankyrin-B heterozygous (ankyrin-B+/-) male littermates.  Four month old male 
Sprague-Dawley rats were also used.  Ankyrin-B null animals die before post-
natal day 1 (Scotland, Zhou et al. 1998), necessitating the use of ankyrin-B+/- 
mice for analyses.   Ankyrin-B+/- mice (Scotland, Zhou et al. 1998) were 
generated by backcrossing at least 18 generations (99.5% pure) into C57Bl/6 
background (Jackson Laboratories) before experiments.  Animals were handled 
according to approved protocols and animal welfare regulations of the 
Institutional Animal Care and Use Committee (IACUC).  Both ankyrin-B+/- and 
control mice were housed in the same facility (identical temperature and 
humidity), consumed the same diet (Lab Diet:  23% protein, 4.5% fat, 6.0% fiber, 
8.0% ash, 2.5% minerals 0.95% Ca+2, 0.67% phosphorus, 0.4% non-phytate 
phosphorus, and 56% complex carbohydrate) from overhead wire feeders and 
water ad libitum, and were kept on identical 12 hour light/dark cycles.  
 51
 Tissue preparation for sectioning.  Pancreatic tissues from wild type 
and ankyrin-B+/- mice were harvested and immediately placed in 10% formalin 
overnight, transferred to 0.50 M sucrose for 12 hours, and returned to 10% 
formalin.  Tissues were embedded in paraffin and sectioned to 10 µm thickness 
by the Vanderbilt University Medical Center Immunohistochemistry Core 
Laboratory.   
 Collection and culture of neonatal cardiac fibroblasts.  Hearts were 
dissected from postnatal day 1 or 2 wild type and ankyrin-B-/- mice and placed in 
2 ml Ham’s F-10 media (Mediatech).  Atrial tissue was excised and the 
ventricular tissue was rinsed to remove residual blood.  Rinsed tissue was 
transferred to 1.5 ml of 0.05% trypsin (Gibco) and 200 µM ethylenediamine 
tetraacetic acid (EDTA) in Ham’s F-10 media.  Tissue was minced using forceps 
and scissors and incubated in trypsin-EDTA at 37 ⁰C for 15 minutes.  Following 
trituration of minced tissue, the minced ventricular tissue was incubated for an 
additional 15 minutes at 37 ⁰C.  Two hundred microliters of soybean trypsin 
inhibitor (2 mg/ml; Worthington) and 200 µl of collagenase (0.2 mg/ml, 1980 
U/mg; Sigma) were incubated with the disrupted cells for 50 minutes at 37 ⁰C.  
The cell suspension was pelleted, resuspended in complete media (40% 
Dulbecco’s Modified Eagle Medium (DMEM), 40% Ham’s F-10 media, and 20% 
fetal bovine serum (FBS; HyClone)), and plated on culture dishes.  After five 
hours, nonadherent cells (cardiomyocytes) were aspirated from the plate.  
Isolated fibroblasts were maintained in DMEM + 10% FBS + 0.1% 
streptomycin/penicillin at 37 ⁰C with 5% CO2. 
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 Immunofluorescent staining.  Paraffinized tissue slices were 
deparaffinized by incubation in xylene for 40 minutes followed by 10 minute 
washes in 100% and 95% ethanol.  Deparaffinized slides were pre-incubated in 
3% fish gelatin (Sigma) for three hours at 4 ⁰C.  Primary antibody staining 
proceeded for 12 hours at 4 ⁰C, followed by extensive washing in 2% fish gelatin 
+ 0.1% Triton X-100 (IF Wash Buffer).  Secondary antibody incubation with the 
appropriate fluorophore-conjugated antibody was carried out for four hours at 4 
⁰C, followed by extensive washing in IF Wash Buffer.  Stained sections were 
mounted with VectaShield (Vector Laboratories) mounting media and 
coverslipped (#1 coverslides, Electron Microscopy Sciences).  Slides were 
protected from light and stored at 4 ⁰C until analysis.  Thirty minutes prior to 
confocal microscopy, the slides were allowed to acclimate to room temperature. 
  Confocal microscopy.  Immunofluorescently-stained images were 
collected on a Zeiss 510 Meta confocal microscope (40 power-water corrected 
numerical aperature 1.2 (Zeiss), pinhole equals 1.0 Airy Disc or 63 power-oil 1.5 
numerical aperature (Zeiss), pinhole equals 1.0 Airy Disc) using Carl Zeiss 
Imaging Software.  Images were imported into Adobe Photoshop for cropping 
and linear contrast adjustment.  
 Tissue collection and preparation for immunoblot analysis.  For 
quantitative immunoblotting and co-immunoprecipitation analysis, pancreatic and 
heart tissues were flash frozen in liquid nitrogen and ground into a fine powder.  
The powder was resuspended in three volumes of ice-cold 50 mM Tris HCl (pH 
7.35), 10 mM NaCl, 0.32 M sucrose, 5 mM EDTA, 2.5 mM ethyleneglycol bis (2-
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amino ethyl ether)-N,N,N’ tetraacetic acid (EGTA), 1 mM phenylmethyl sulfonyl 
fluoride (PMSF), 1 mM 4-(2-aminoethyl) benzenesulfonylfluoride hydrochloride 
(AEBSF), 10 µg/ml leupeptin, and 10 µg/ml pepstatin (Homogenization Buffer) 
using a Beckman Polytron homogenizer.  The homogenate was centrifuged at 
1,000 x g at 4 ⁰C to remove nuclei.  Triton X-100 and deoxycholate were added 
to the post-nuclear supernatant for final concentrations of 1.5% Triton X-100 and 
0.75% deoxycholate.  The lysate was pelleted at 100,000 x g for one hour at 4 
⁰C.  The resulting supernatant was quantitated by bicinchoninic acid assay (BCA 
Protein Assay Kit, Pierce) followed by spectrophotometric determination at 562 
nm.  Equal amounts of protein were loaded on gradient gels. 
 SDS-PAGE and immunoblot analysis.  Equal amounts of protein were 
diluted in reducing agent and loading buffer and boiled for five minutes.  Reduced 
lysates were loaded onto either a 3-8% Tris-acetate gel (NuPAGE, Invitrogen) or 
a 4-12% bis-tris acrylamide gel (NuPAGE, Invitrogen) and electrophoresed at 
100 mV for 15 minutes followed by 150 mV for two hours.  Electrophoresed 
proteins were transferred to nitrocellulose (Hybond ECL Nitrocellulose, 0.45 µm 
pore size; GE Healthcare) and blocked for three hours in 5% non-fat dry milk 
(NFDM) in TTBS.  Primary antibodies were diluted in 5% NFDM and incubated 
with nitrocellulose blots for 12 hours at 4 ⁰C with gentle agitation, followed by 
three washes in TTBS for 15 minutes at room temperature.  Secondary 
antibodies were diluted in 5% TTBS and incubated with nitrocellulose blots for 
three hours at 4 ⁰C, followed by three washes in TTBS for 15 minutes at room 
temperature.  Washed blots were rinsed in chemiluminescent solution 
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(SuperSignal West Pico Chemiluminescent Substrate, Pierce) for one minute and 
exposed to autoradiography film (Classic Blue Autoradiography Film, 
Midamerican Scientific).  Films were scanned and band intensity quantitated 
using QuantityOne software (BioRad).   
 Antibodies.  The following primary antibodies were used for 
immunofluorescent staining and/or immunoblotting protocols:  anti-ankyrin-B 
(polyclonal and monoclonal) (Mohler, Gramolini et al. 2002), anti-ankyrin-G 
(polyclonal) (Mohler, Rivolta et al. 2004), anti-Kir6.2 (polyclonal, Alomone labs), 
anti-Kir6.1 (polyclonal, Alomone labs) anti-SUR1 (polyclonal, Santa Cruz 
Biotechnology), anti-SUR2A (goat polyclonal, Santa Cruz Biotechnology), anti-
InsP3 receptor (polyclonal, Upstate), anti-NHERF1 (sodium-hydrogen exchange 
regulatory factor 1; polyclonal) (Mohler, Kreda et al. 1999), anti-NCX1 
(monoclonal, RDI), anti-NKA (polyclonal, Upstate), anti-Cav1.2 (polyclonal, 
Affinity Bioreagents), anti-phalloidin-568 (Molecular Probes), ToPro-3 DNA stain 
(Molecular Probes), anti-glucagon (monoclonal, Sigma), anti-green fluorescent 
protein (GFP, polyclonal) (Mohler, Gramolini et al. 2002), and anti-hemagglutinin 
(HA, monoclonal) (Mohler, Rivolta et al. 2004).  Secondary antibodies for 
immunoblot analysis included horseradish peroxidase (HRP) conjugated donkey 
anti-rabbit (Jackson Laboratories), donkey anti-mouse (Jackson Laboratories), 
and donkey anti-goat (Jackson Laboratories).  Secondary antibodies for 
immunofluorescent staining included Alexa-488 donkey anti-rabbit (Molecular 
Probes), Alexa-568 donkey anti-rabbit (Molecular Probes), Alexa-488 donkey 
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anti-mouse (Molecular Probes), and Alexa-568 donkey anti-mouse (Molecular 
Probes). 
 RNA preparation.  Following anesthesia and cervical dislocation, still-
beating hearts were excised and flash frozen in liquid nitrogen.  Total RNA from 
pools of heart tissues was isolated and DNase-treated using the RNeasy Fibrous 
Tissue Micro Kit (Qiagen) per manufacturer’s protocols.  The quality of total RNA 
was assessed by polyacrylamide gel microelectrophoresis (Agilent 2100 
Bioanalyzer).  Genomic DNA contamination was assessed by PCR amplification 
of total RNA samples without prior cDNA synthesis and no genomic DNA was 
detected. 
 TaqMan quantitative RT-PCR.  TaqMan Low Density Arrays (TLDA, 
Applied Biosystems) were completed in a two step RT-PCR process.  Briefly, first 
strand cDNA was synthesized from 200 ng of total RNA by using the High-
Capacity cDNA Archive Kit (Applied Biosystems).  PCR reactions were carried 
out in TLDA by using the ABI PRISM 7900HT Sequence Detection System 
(Applied Biosciences).  The 384 wells of each array were preloaded with 96 x 4 
pre-designed 6-fluorescein (FAM)-labelled fluorgenic TaqMan Kir6.2 and ankyrin-
B probes and primers.  The probes were labelled with the fluorescent reporter 
dye 6-carboxyfluorescein (FAM, Applera Corporation) on the 5’ end and with a 
nonfluorescent quencher on the 3’ end.  Two nanograms of cDNA from each 
sample was combined with 1X TaqMan Universal Master Mix (Applied 
Biosystems) and loaded into each well.  The TLDA were cycled at 50 ⁰C for two 
minutes and 94.5 ⁰C for ten minutes, followed by 40 cycles of 97 ⁰C for 30 
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seconds and 59.7 ⁰C for one minute.  Data were collected with instrument 
spectral compensations by using the Applied Biosystems SDS 2.2.1 software 
and analyzed by using the comparative threshold cycle (CT) relative 
quantification method.  The GAPDH gene was used as an endogenous control to 
normalize the data.  Results in wild type and ankyrin-B+/- animals were expressed 
as relative mRNA expression level as compared with GAPDH.   
 Statistics.  When appropriate, data were analyzed using a two-tailed t test 
with p < 0.05 considered significant or ANOVA.  Values are expressed as the 
mean + standard deviation.  For immunoblot analysis, radiographs were 
quantitated using QuantityOne software followed by statistical analysis with 
Sigma Plot software (SigmaPlot).  
 Co-immunoprecipitation.  Protein-A-conjugated agarose beads 
(Rockland) were incubated with either affinity-purified polyclonal anti-ankyrin-B or 
control mouse IgG in PBS with 0.1% Triton X-100 and protease inhibitors 
(Sigma) (Co-IP Binding Buffer) for 12 hours at 4 °C with rotation.  Beads were 
centrifuged and washed three times in ice-cold PBS.   Nine milligrams of rat 
pancreatic or rat heart tissue lysate were added to washed beads, along with 
protease inhibitor cocktail (Sigma) and 500 µl Co-IP Binding Buffer, and 
incubated at 4 °C for 12 hours with rotation.  Following incubation, the mixtures 
were centrifuged and washed three times in ice-cold Co-IP Binding Buffer.  
Proteins were eluted by adding loading buffer plus dithiothreitol (DTT) and boiled 
for five minutes.  Samples were centrifuged and 25 µl of supernatant were loaded 
onto a 3-8% Tris-acetate gradient gel.  Proteins were electrophoresed at 100 mV 
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for 15 minutes and 150 mV for two hours.  Separated proteins were transferred 
to nitrocellulose and pre-blocked in 5% NFDM in TBS plus Tween-20 (TTBS) for 
three hours at 4 °C.  Anti-Kir6.2 polyclonal antibodies or anti-Kir6.1 polyclonal 
antibodies were added to 5% NFDM in TTBS and incubated with nitrocellulose 
blots for 12 hours at 4 °C.  Blots were washed three times in TTBS and incubated 
in 5% NFDM with donkey anti-rabbit HRP-conjugated secondary antibodies for 
three hours at 4 °C, followed by extensive washing in TTBS.  Washed blots were 
rinsed in chemiluminescent reagent for one minute and exposed to 
autoradiography film. 
 Cloning of Kir6.2 cDNA from human GAL4 cardiac cDNA library and 
subcloning into pBluescript-SK vector.  Primers were designed to clone Kir6.2 
cDNA from the human GAL4 cardiac cDNA library (BD Biosciences) based on 
the sequence obtained from GenBank (NM 000525).  To facilitate subcloning, 
primers were designed to incorporate 5’ EcoRI and 3’ BamHI restrictions sites.  
Forward primer:  5’ GCC GAA TTC ATG CTG TCC CGC AAG GGC ATC AT 3’; 
Reverse primer:  5’ GGC GGA TCC TCA GGA CAG GGA ATC TGG AGA 3’.  
PCR products were run out on a 1% agarose gel plus ethidium bromide (0.17 
mg/ml) at 100 mV and gel purified (Gel Extraction Kit, Qiagen).  Purified PCR 
products, along with the pBluescript-SK expression vector (Stratagene), were 
digested with EcoRI (20 units; New England Biolabs) and BamHI (20 units; New 
England Biolabs) for five hours at 37 °C.  Digested vector was further incubated 
with calf intestinal alkaline phosphatase (0.01 µg/µl, Promega) for two hours at 
37 ⁰C.  Digested products were separated on a 1% agarose plus ethidium 
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bromide gel and purified.  Ligation of digested Kir6.2 and pBluescript-SK vector 
was performed using T4 DNA ligase (LigaFast, Promega) overnight at 4 ⁰C.  
Ligated products were transformed into DH5α Escherichia coli cells using a 
standard heat-shock protocol, plated on Lennox L Broth Base (LB) agar 
containing ampicillin (0.05 µg/µl), and incubated at 37 °C overnight.  Positive 
colonies were expanded and plasmids purified.  Restriction digestion was 
performed to identify potential clones and sequences were verified. 
 Production of Kir6.2 truncated and mutated constructs.  A series of 
mutated and truncated Kir6.2 constructs in the context of the pBluescript-SK 
vector (Table 2) were generated by either PCR-based or site-directed 
mutagenesis protocols.  Site-directed mutants (E321K, E321A, E322K, E322A, 
D323K, and D323A) were generated using the full-length Kir6.2 (in pBluescript-
SK) as a template, along with distinct primers (Table 3) and the QuikChange II 
mutagenesis kit (Stratagene) to incorporate the appropriate mutation (Table 3).  
Kir6.2-NT (amino acids 74-390), Kir6.2-CT (amino acids 1-159), Kir6.2truncA 
(amino acids 1-315), and Kir6.2truncB (amino acids 1-330) were constructed 
using specially-designed primers in a PCR-based reaction to generate the insert 
(flanked by 5’ EcoRI and 3’ BamHI restriction sites), followed by ligation into the 
pBluescript-SK vector using T4 DNA ligase (Promega).  Specifically, Kir6.2-NT 
was designed to be translated beginning with amino acid 74.  Kir6.2-CT was 
generated by inserting a premature stop codon at amino acid position 160.  
Kir6.2truncA introduced a premature stop codon at amino acid 316 (prior to the 
putative ankyrin-B binding site), while Kir6.2truncB introduced a premature stop 
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codon at amino acid 331 (following the putative ankyrin-B binding site). Site-
directed mutants were constructed to introduce either an alanine (A) or lysine (K) 
in place of amino acids E321, E322, or D323.  All sequences were verified by 
sequencing prior to experimentation. 
 Production and purification of ankyrin-B GST-conjugated and 
ankyrin-G GST-conjugated proteins.  cDNAs for the ankyrin-B membrane-
binding domain plus the proximal portion of the spectrin-binding domain (amino 
acids 1-959), the membrane-binding domain (amino acids 1-861), spectrin-
binding domain (amino acids 862-1444), and C-terminal domain (amino acids 
1556-1840), as well as the membrane-binding domain of ankyrin-G (amino acids 
1-886) were PCR-amplified, cloned into pGEX6P-1 (Amersham Biosciences), 
and sequenced to confirm correct sequences.  To facilitate cloning, all constructs 
were engineered to contain 5’ EcoRI and 3’ XhoI restriction sites.  
BL21(DE3)pLysS cells (Invitrogen) were transformed with the ankyrin-B 
pGEX6p-1 constructs and grown overnight at 37 ⁰C in LB supplemented with 
0.05 µg/µl ampicillin.  The overnight cultures were sub-cultured for large-scale 
expression.  Cells were grown to an optical density of 0.6-0.8 and induced with 1 
mM isopropyl 1-thio-β-D-galactopyranoside (IPTG) for two hours at 37 ⁰C.  Cells 
were centrifuged for 10 minutes at 8,000 x g, resuspended in PBS, and frozen at 
-80 ⁰C following resuspension.  Cells were lysed by thawing.  The crude extract 
was suspended in a solution of PBS, 1 mM DTT, 1 mM EDTA, 40 µg/ml AEBSF, 
10 µg/ml leupeptin, 40 µg/ml benzamidine, 10 µg/ml peptstatin (Lysis Buffer) and  
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Table 2.  Kir6.2 constructs used in in vitro binding and/or transfection 
experiments. 
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Table 3.  Primers used to engineer unique Kir6.2 constructs. 
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was pushed through a 22-gauge syringe to shear bacterial DNA.  Cell debris was 
removed by centrifugation at 11,000 x g for one hour at 4 ⁰C.  Supernatants were 
added to 2 ml of equilibrated glutathione-agarose (Amersham Biosciences) in 
small batches for four hours at 4 ⁰C.  The glutathione-agarose was washed with 
PBS containing 0.65 M NaCl and eluted using 50 mM Tris-HCl, 10 mM 
glutathione, 1 mM EDTA, 1 mM DTT, pH 8.0 (Elution Buffer).  Protein sizes were 
verified by SDS-PAGE and Coomassie staining.  Purified protein was quantitated 
using the BCA method. 
 In vitro transcription/translation and binding experiments.  Kir6.2 
constructs (Table 2) were in vitro transcribed/translated using rabbit reticulocyte 
lysate, [35S]-methionine (20 µCi of Redivue L-[35S]-methionine (GE Healthcare), 
T7 polymerase, and 0.75 µg plasmid DNA (TNT Coupled Rabbit Reticulocyte 
Lysate System, Promega).  For binding experiments, 20 µg of purified glutathione 
S-transferase (GST) or GST-ankyrin-B membrane-binding domain (MBD) were 
coupled to glutathione sepharose for two hours at 4 ⁰C in 50 mM Tris-HCl pH 7.4, 
1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 0.1% Triton X-100 (IV Binding Buffer).  
Following extensive washes in 50 mM Tris-HCl pH 7.3, 1 mM EDTA, 1 mM 
EGTA, 500 mM NaCl, 1% Triton X-100 (IV Wash Buffer), conjugated beads were 
incubated with Kir6.2 in vitro translation products for four hours at 4 ⁰C in IV 
Binding Buffer plus protease inhibitor cocktail.  Following incubation, binding 
reactions were washed five times in IV Wash Buffer, eluted by boiling in loading 
buffer and reducing agent, and analyzed by SDS-PAGE.  Gels were stained with 
Coomassie to show presence of in vitro translated and GST proteins (and to 
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confirm equal loading of proteins into the binding reactions) prior to drying the gel 
using a gel dryer (Biorad).  Radiolabelled proteins were detected by 
phosphorimaging.   
 Pull-down analysis.  Two biotinylated Kir6.2 oligopeptides (WT:  
GQRFVPIVAEEDGR and MUT:  GQRFVPIVAEKDGR; Biosynthesis, Inc.) were 
constructed with an SGSG linker between the biotin and the Kir6.2 sequence.  
Twenty micrograms of oligopeptide were conjugated to 40 µl bead volume of 
strepavidin beads (Thermo Scientific) for four hours at 4 ⁰C in IV Binding Buffer.  
The beads were washed extensively in IV Binding Buffer and 10 µg of purified 
ankyrin-B MBD-GST were added to the washed beads, along with 500 µl of IV 
Binding Buffer.  The reactions were incubated overnight at 4 ⁰C with gentle 
rotation.  The reactions were centrifuged and washed five times in IV Binding 
Buffer.  Elution was performed by boiling the beads in loading buffer and 
reducing agent for five minutes.  Eluted solutions were centrifuged and separated 
by SDS-PAGE.  Separated proteins were transferred to nitrocellulose and 
incubated overnight at 4 ⁰C in a solution of 5% TTBS plus anti-ankyrin-B 
antibodies.  Blots were washed three times (15 minutes each) in TTBS before 
incubation with donkey anti-rabbit antibodies diluted in 5% TTBS for three hours 
at 4 ⁰C.  Blots were washed three times (15 minutes each) in TTBS and 
incubated for one minute in chemiluminescent reagent and exposed to 
autoradiography film. 
 Subcloning of Kir6.2 constructs into a GFP-fusion vector.  In order to 
generate Kir6.2 constructs engineered with a C-terminal GFP fusion, a PCR-
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based approach to produce full-length and mutant Kir6.2 fragments.  Specifically, 
primers were designed to incorporate 5’ EcoRI and 3’ BamHI restriction sites to 
facilitate ligation.  Additionally, the termination codon was removed from each 
construct in order to allow the expression of the C-terminal GFP gene.  The PCR 
products were ligated into the pAcGFP1N2 expression vector (Clontech).  
Positive clones were identified by restriction digestion and the sequences verified 
prior to experimentation.   
 Cell culture.  HEK293 cells were maintained DMEM (Gibco) 
supplemented with 10% FBS (HyClone) and 0.1% penicillin/streptomycin.  Cells 
were kept at 37° C in 5% CO2. COSm6 cells (a gift from Dr. Colin Nichols at 
Washington University, St. Louis) were cultured in DMEM supplemented with 
10% FBS and 0.1% penicillin/streptomycin.  Cells were kept at 37° C in 5% CO2. 
 Transfection of HEK293, COSm6, and cardiac fibroblast.  Cultured 
cells and fibroblasts were split 24 hours prior to transfection (30% confluence at 
time of transfection).  Qiagen Effectene reagent and corresponding 
manufacturer’s instructions were used to co-transfect cells with SUR1 and Kir6.2-
GFP, Kir6.2-E322K-GFP, or empty pAcGFP1N2 cDNA constructs (5:1 SUR1 
cDNA to GFP construct cDNA).  Transfection was carried out for nine hours at 37 
°C and the cells were allowed to recover overnight.  Transfected cells were 
plated on Mattek plates (Mattek Cultureware) for further immunolabeling, 
confocal analysis, and electrophysiological analysis. 
 Isolation of pancreatic islets.  Mice were anesthetized with 2-bromo-2-
chloro-1,1,1-trifluoroethane (Sigma) in an anesthetizing chamber and killed by 
 65
cervical dislocation, in accordance with IACUC standards.  Pancreata were 
cannulated and injected with Hank’s balanced salt solution (Sigma) containing 
type XI collagenase (Sigma; 0.3 mg/ml, pH 7.4).  The pancreata were digested 
for five minutes at 37 ⁰C, hand-shaken and washed three times in Hank’s 
solution.  Islets were manually isolated under a dissecting microscope and 
maintained overnight in CMRL medium (Gibco BRL; containing 5.6 mM glucose) 
in a humidified 37 ⁰C incubator.  Trypsin-treated islets were dispersed into 
isolated cells by resuspending gently in complete CMRL medium (supplemented 
with 10% FCS), penicillin (100 U/ml) and streptomycin (100 µg/ml).  Isolated cells 
were plated on glass coverslips. 
 Rubidium flux experiments.  Cells were pre-incubated for one hour with 
86Rb+ (in the form of rubidium chloride, 1.5 mCi/ml; Amersham Biosciences).  
Loaded cells were washed twice with RPMI-1640 medium (Sigma) at 37 ⁰C.  
86Rb+ efflux was assayed by replacing the bath solution with Ringer’s solution 
containing metabolic inhibitor (MI), with or without 1 µM glibenclamide.  MI 
solution contained 2.5 mg/ml oligomycin, 1 mM 2-deoxyglucose, along with 10 
mM tetraethylammonium to inhibit voltage-gated K+ channels and 10 µM 
nifedipine to block Ca2+ entry.  The bath solution was replaced with fresh solution 
every five minutes over a 40 minute time period and counted in a scintillation 
counter.  86Rb+ efflux in the presence or absence of glibenclamide was fitted by a 
single exponential.  The reciprocal of the exponential time constant (rate 
constant) for each efflux experiment is then proportional to the K+ (Rb+) 
conductance in the cell membranes. 
 66
 Electrophysiological analysis.  Macroscopic currents from dispersed 
cells were recorded using standard whole-cell voltage-clamp configuration 
(Koster, Remedi et al. 2002).  Electrodes were filled with K-INT (140 mM KCl, 10 
mM K-HEPES, 1 mM K-EGTA, pH 7.4) plus 1 mM MgCl2 and 1 mM ATP 
(potassium salt).  Experiments were digitized into a microcomputer using 
Pclamp8.0 (Axon Instruments, La Jolla, CA) software.  Off-line analysis was 
performed in Microsoft Excel. 
 Mathematical Modeling.  Pancreatic beta cell electrical activity was 
simulated using the mathematical model developed by Fridlyand et al. (Fridlyand, 
Tamarina et al. 2003). This model has been used with to generate insight into 
molecular mechanisms underlying the oscillations in transmembrane potential 
that trigger insulin release from pancreatic beta cells.  Importantly, this model 
accounts for dynamic changes in intracellular ATP levels that regulate cell 
excitability through IKATP.  The model includes a detailed formulation for the 
fraction of open KATP channels {Fridlyand, 2003 #1775; Magnus, 1998 #1776}: 
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Ktd and Kdd values of 57 µM and 31 µM, respectively, were used as measured by 
Hopkins et al. in excised, inside-out patches from adult mouse pancreatic beta 
cells (Hopkins, Fatherazi et al. 1992).  Values for h and Ktt (1.32 µM and 15 µM, 
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respectively) were chosen to agree with observed measurements in COSm6 
cells.  The E322K mutation is in the ankyrin-B binding domain of Kir6.2.  The 
data in this study show that the mutation affects channel trafficking as well as 
ATP sensitivity. The following assumptions in this model were made of the 
E322K heterozygous mutant: 1) E322K and WT subunits are incorporated with 
equal probability into tetrameric channels, resulting in five functionally distinct 
populations (Figure 7): 4 WT, 3 WT:1 mutant, 2 WT:2 mutant, 1 WT:3 mutant, 4 
mutant; 2) Kir6.2 subunits exert an additive effect on the open state probability of 
the tetrameric channel (Craig, Ashcroft et al. 2008), such that given the ATP 
sensitivity of each individual subunit, the sensitivity of the tetramer can be 
determined as 1/Ktt,tetr = 1/Ktt,1 + 1/Ktt,2 + 1/Ktt,3 + 1/Ktt,4; 3) KATP tetrameric 
channels will traffic differently depending on their stoichiometry.  For example, 
KATP channels with four mutant subunits will display the most severe trafficking 
defect due to loss of ankyrin-B binding at all four subunits, while channels with 
four WT subunits will traffic normally.    
 ATP sensitivity and peptide competition assays.  COSm6 cells were 
transfected with cDNAs encoding Kir6.2 (with mutations as described, and a C-
terminal GFP tag), and SUR1, using the Fugene 6 transfection reagent (Roche). 
Patch-clamp experiments were made at room temperature, using the Dynaflow 
microfluidic capillary chip-based platform (Cellectricon, Inc.) and DF-16ProII 
chips. This device generates laminar flow at solution outlets to prevent mixing 
between solutions, and a computer-controlled stepper motor is used to move the 
chip relative to the patch pipette, allowing for rapid solution exchange around the 
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membrane patch. This device also minimizes the amount of peptide reagents 
necessary for the experiment. Data were normally filtered at 0.5-2 kHz, signals 
were digitized at 5 kHz and stored directly on computer hard drive using Clampex 
software (Axon, Inc.). The standard pipette (extracellular) and bath (cytoplasmic) 
solutions had the following composition: 140 mM KCl, 1 mM K-EGTA, 1 mM K-
EDTA, 4 mM K2HPO4, pH 7.3. Peptides were stored as 500 µM stocks (made up 
in standard recording solution) at -20 ⁰C, and diluted to working concentrations 
on each experimental day. ATP was stored as a 100 mM stock (dipotassium 
salt), with the pH previously adjusted to 7.3, and diluted for each experiment. 
 
Results  
Ankyrin-B+/- mice display abnormal Kir6.2 expression and localization 
 
   Ankyrin-B is highly expressed in pancreatic beta cells (Figure 8A), with 
minimal levels observed in other pancreatic islet cell types (Figure 8A, C) 
{Mohler, 2007 #1368}.  Moreover, ankyrin-B is not significantly expressed in 
pancreatic exocrine acinar cells (Figure 8B, D).  Mice heterozygous for an 
ankyrin-B null mutation (ankyrin-B+/- mice) are viable and express significantly 
less islet ankyrin-B levels (Figure 8C, D) (Mohler, Healy et al. 2007).   
 Ankyrins are required for the targeting of ion channels, transporters, and 
pumps in a host of tissues (Bennett and Baines 2001).  To identify the role of 
ankyrin-B in the beta cell, expression and localization of a number of key beta 
cell ion channels, transporters, and cytoskeletal proteins in ankyrin-B+/- pancreas 
were evaluated.  There was a striking reduction in expression levels of Kir6.2 
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(Figure 9G and Figure 10B, >50%, n=10, p<0.05), the α-subunit of the KATP 
channel in ankyrin-B+/- pancreas and a complete loss of Kir6.2 expression in 
ankyrin-B null pancreatic lysates (Figure 12A). In contrast, there were no 
differences in expression of the L-type calcium channel Cav1.2, SUR1, ankyrin-
G, or NHERF1 by immunoblot (Figure 9B, C, F, I, and J and Figure 10D, E, G).  
Moreover, the levels of two membrane proteins affected by loss of ankyrin-B in 
heart, NCX1 and NKA (Mohler, Schott et al. 2003; Mohler, Davis et al. 2005; 
Cunha, Bhasin et al. 2007), were unchanged in ankyrin-B+/- pancreatic tissue 
(Figure 9D, E and Figure 10C, F).   As expected, there was a significant 
reduction in ankyrin-B expression in ankyrin-B+/- pancreas as compared with wild 
type (Figure 9I and Figure 10A) and a complete loss of ankyrin-B expression in 
pancreatic lysates from ankyrin-B null mice (Figure 12B). 
 Reduction in Kir6.2 levels as analyzed by immunoblot was paralleled by 
Kir6.2 immunostaining in ankyrin-B+/- pancreatic islets.  Specifically, there was a 
striking reduction in the expression of Kir6.2 in ankyrin-B+/- beta cells (Figure 9K, 
L), while the expression of other key beta cell proteins was unaffected (see 
Cav1.2 in Figure 9I, J).  Additionally, real-time PCR revealed no significant 
difference in the levels of mRNA encoding Kir6.2 (KCNJ11), suggesting that the 
abnormal expression of Kir6.2 in ankyrin-B+/- pancreas is likely due to post-
transcriptional events (Figure 11).  Together, these findings support a potential 
role for ankyrin-B in the expression of Kir6.2 in excitable cells.   
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Figure 8.  Ankyrin-B is highly expressed in beta cells of pancreatic islets. 
 
(A)  High magnification of wild type pancreatic islets demonstrates significant 
beta cell expression of ankyrin-B.  Additionally, ankyrin-B expression is limited to 
the pancreatic beta cells, with negligible expression in the exocrine tissue (B and 
D; low magnification view of the pancreatic islets) or alpha cells (anti-glucagon 
staining, panels A and C).  As anticipated, the expression of ankyrin-B in ankyrin-
B+/- islets (C and D) is significantly reduced as compared to wild type (A and B).  
Scale bar equals 10 microns. 
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Figure 9.  Expression and localization of the pore-forming subunit of the 
KATP channel, Kir6.2, is reduced in pancreatic tissue from ankyrin-B+/- mice.   
 
(A)  Ankyrin-B+/- pancreatic lysates express significantly less ankyrin-B than wild 
type while there are no significant differences in the expression of (B)  NHERF1, 
(C)  Ankyrin-G, (D) NKA, (E) NCXI, (F) SUR1, and (I) and (J) Cav1.2.  The 
expression of Kir6.2 is significantly reduced in pancreatic lysates from ankyrin-
B+/- mice as analyzed by immunoblot (G) and in pancreatic islets as analyzed by 
immunofluorescent staining (K and L).  (H)  Coomassie staining and (B) NHERF1 
staining confirm equal loading of protein.  Scale bar equals 10 microns. 
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Figure 10.  Differences in ankyrin-B and Kir6.2 expression from wild 
type and and ankyrin-B+/- pancreatic lysates is statistically significant.   
 
(A and B)  A two-tailed t-test demonstrated that differences in ankyrin-B and 
Kir6.2 expression between wild type and ankyrin-B+/- pancreatic lysates are 
significantly different (p <0.002), while there are no statistical differences in 
the expression levels of (C) NKA, (D) ankyrin-G, (E)  NHERF1, (F) NCX1, and 
(G) SUR1 between wild type and ankyrin-B+/- pancreatic lysates. 
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Figure 11.  There is no significant difference in Kir6.2 mRNA levels 
between wild type and ankyrin-B+/- tissues.   
 
Quantitative real-time polymerase chain reaction (qRT-PCR) demonstrates no 
significant difference in the mRNA levels of Kir6.2 between wild type and 
ankyrin-B+/- tissue, suggesting that differences in protein levels are due to a 
post-transcriptional event. 
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Figure 12.  Ankyrin-B null pancreatic lysates do not express discernible 
levels of Kir6.2 or ankyrin-B.   
 
Pooled pancreata from post-natal day 1 wild type, ankyrin-B+/-, and ankyrin-B 
null mice were analyzed by immunoblot.  While ankyrin-B+/- pancreatic lysates 
express significantly less Kir6.2 (A) and ankyrin-B (B) than wild type, there is 
no discernable expression of either Kir6.2 or ankyrin-B in ankyrin-B null 
pancreatic lysates. 
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Islets isolated from ankyrin-B+/- mice demonstrate decreased insulin 
secretion 
 
 To demonstrate an in vivo response to decreased ankyrin-B expression 
levels on islet activity, islets were isolated from six month old wild type and 
ankyrin-B+/- mice.  These islets were analyzed for the ability to secrete insulin in 
response to 23 mM glucose (stimulatory concentration used in insulin secretion 
assays).  Ankyrin-B+/- islets demonstrate a subtle, but statistically significant, 
decrease in insulin secretion compared to wild type islets (Figure 13A).  In order 
to demonstrate that the decrease in insulin secretion is not due to any differences 
in islet insulin content, the insulin content of five isolated islets from both wild 
type and ankyrin-B+/- pancreata was measured.  According to Figure 13B, there 
is no significant difference in the insulin content of wild type and ankyrin-B+/- 
islets, suggesting that any differences in insulin secretion is not due to 
differences in islet insulin content.  Since decreased insulin secretion is 
associated with hyperglycemia, fasting blood glucose levels were measured.  
Ankyrin-B+/- mice are significantly more hyperglycemic than wild type, suggesting 
an abnormality in insulin secretion in these mice. 
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Figure 13.  Islets from ankyrin-B+/- mice secrete less insulin than wild 
type islets under stimulatory conditions. 
 
(A)  Pancreatic islets isolated from wild type and ankyrin-B+/- mice were 
stimulated with 23 mM glucose and insulin secretion measured after one 
hour.  Islets from ankyrin-B+/- mice secrete significantly less insulin in 
response to 23 mM glucose than wild type.  (B)  Islets were analyzed for 
insulin content, demonstrating no significant differences in insulin content 
between the isolated islets from wild type and ankyrin-B+/- mice.  (C)  Ankyrin-
B+/- mice exhibit hyperglycemia with fasting blood glucose levels significantly 
higher than wild type. 
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Ankyrin-B co-immunoprecipitates with Kir6.2 in the pancreas and heart 
 
 Co-immunoprecipitation experiments were performed to evaluate a 
potential in vivo ankyrin-B/Kir6.2 interaction.   Affinity-purified ankyrin-B Ig co-
immunoprecipitates Kir6.2 from detergent-soluble lysates generated from rat 
pancreas and rat heart (Figure 14A).  No interaction between Kir6.2 and control 
Ig was observed (Figure 14A).  Moreover, ankyrin-B was unable to co-
immunoprecipitate the Kir6.1 isoform from cardiac tissue (Figure 14B), 
suggesting that ankyrin-B interaction is specific for Kir6.2.   
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Figure 14.  Ankyrin-B associates in vivo with Kir6.2 in both pancreas and 
heart.   
 
(A)  Kir6.2 co-immunoprecipitates with ankyrin-B from rat pancreatic lysate using 
affinity-purified anti-ankyrin-B antibodies, while control antibodies show no non-
specific association.  (B)  Ankyrin-B and Kir6.2 also co-immunoprecipitate from 
rat heart lysate, while (C) ankyrin-B and Kir6.1 do not.  Control antibodies show 
no non-specific association in heart lysate. 
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Ankyrin-B MBD directly interacts with in vitro translated full-length Kir6.2 
 
 A potential direct ankyrin-B/Kir6.2 interaction was explored using purified 
proteins.  GST-fusion proteins corresponding to the three major domains of 
ankyrin-B (MBD, SBD, and CTD regulatory domains, Figure 15A) were 
generated and purified from bacteria (Figure 15C).  In vitro binding assays using 
radiolabeled full-length Kir6.2 revealed a direct interaction of the ankyrin-B MBD 
(Figure 15B).  Both the ankyrin-B SBD and CTD displayed binding activity below 
background (Figure 15B).  Since the ankyrin-B MBD fusion protein used for 
binding experiments in Figure 14B contains 180 residues of the SBD N-terminus 
(Mohler, Davis et al. 2004), a new fusion protein lacking these SBD residues was 
generated to verify that binding occurred solely within the MBD.  As shown in 
Figure 15D, residues within the MBD are sufficient for Kir6.2 interaction.  In fact, 
significant ankyrin-B MBD/Kir6.2 binding was detected even in salt 
concentrations as high as 500 mM (Figure 15E).  Together, these new findings 
support that ankyrin-B and Kir6.2 are protein partners in vivo and that this direct 
interaction is mediated by the ankyrin-B MBD.   
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Figure 15.  Ankyrin-B associates with Kir6.2 in vitro. 
 
(A and B)  In vitro translated full-length Kir6.2 associates with the MBD 
containing a portion of the SBD of ankyrin-B, but shows no significant association 
with the SBD or CTD of ankyrin-B.  (C)  Coomassie staining demonstrating equal 
amounts of GST-ankyrin-B MBD, SBD, and CTD were used in the in vitro binding 
assay.  (D)  In vitro translated Kir6.2 associates with the ankyrin-B MBD (note 
loading of GST-ankyrin-B MBD and GST alone) and this interaction persists at 
salt concentrations as high as 500 mM NaCl (top panel, E; bottom panel 
demonstrates equal loading of purified GST proteins).  
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Ankyrin-B MBD interacts with the C-terminal cytoplasmic domain of Kir6.2 
 
 Kir6.2 has two transmembrane domains:  a cytosolic N-terminus (residues 
1-73) and a cytosolic C-terminus (residues 161-390) (Figure 16A).  Ankyrin is a 
strictly cytosolic protein; therefore, association with Kir6.2 should be limited to 
cytosolic domains.  To establish the structural requirements on Kir6.2 for ankyrin-
B association, Kir6.2 mutant polypeptides were generated that lacked either the 
N- or C-terminal cytoplasmic domains (Kir6.2-NT and Kir6.2–CT, respectively; 
Figure 16B, C).  Radiolabeled full-length and mutant Kir6.2 proteins were 
incubated with immobilized GST-ankyrin-B MBD or GST alone.  Similar to full-
length Kir6.2, there was significant binding of Kir6.2-NT with GST-ankyrin-B MBD 
(Figure 16D, E).  In contrast, Kir6.2 lacking the cytoplasmic C-terminus lacked 
ankyrin-binding activity (Figure 16F), even though the ankyrin-B polypeptide was 
present at equivalent levels (Figure 16G).  These findings establish the Kir6.2 C-
terminal cytoplasmic domain as the site of ankyrin-B/Kir6.2 interaction.   
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Figure 16.  Ankyrin-B associates with the C-terminal cytoplasmic domain of 
Kir6.2.   
 
(A)  In vitro translated full-length Kir6.2 and Kir6.2 engineered to remove the (B)  
N-terminal cytoplasmic portion (residues 1-73) are able to associate with the 
membrane-binding domain of ankyrin-B (D and E), while Kir6.2 engineered to 
remove the (C) C-terminal cytoplasmic domain (residues 160-390) loses 
interaction with ankyrin-B (F).  (G)  Coomassie stain demonstrating equal 
amounts of GST-ankyrin-B MBD or GST alone were added to each reaction. 
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An eight amino acid motif in the C-terminal domain of Kir6.2 is both 
necessary and sufficient for interaction with ankyrin-B 
 
 Ankyrin-G interacts with voltage-gated Nav channel isoforms via a 
conserved cytoplasmic motif (Garrido 2003; Lemaillet 2003; Mohler 2004) (Figure 
17A).  A similar motif has also been recently described in Kv2.1 and Kv3.1 
channels (Chung 2006; Pan 2006; Rasmussen 2007). Analysis of the primary 
sequence of the Kir6.2 C-terminus revealed an eight amino acid motif strikingly 
similar to the ankyrin-binding motif found on Nav and Kv channels (Figure 17B).  
This motif is conserved across species (Figure 17B) and is not represented in 
human Kir6.1 (Figure 17B).  We evaluated the role of this motif for ankyrin-
binding using in vitro binding assays and two Kir6.2 mutants.  The first mutant 
was engineered with a premature stop codon following the putative ankyrin-
binding motif (Kir6.2 1-330 (Kir6.2truncB), Figure 17D), while the second mutant 
was engineered with a premature stop codon preceding the putative ankyrin-
binding motif (Kir6.2 1-314 (Kir6.2truncA), Figure 17E).  In vitro binding with 
immobilized GST-ankyrin-B MBD revealed that only the Kir6.2 1-330 mutant 
displayed binding activity for ankyrin-B (Figure 18G), similar to that of full-length 
Kir6.2 (Figure 17C, F).  Binding of Kir6.2 1-314 for GST-ankyrin-B MBD was 
similar to GST alone (Figure 17H).  These data suggest that an eight residue 
motif found in other ankyrin-binding partners is necessary for the interaction of 
Kir6.2 with ankyrin-B.   
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Figure 17.  A C-terminal eight amino acid motif in Kir6.2 is necessary for 
interaction with ankyrin-B MBD.   
 
(A)  Evaluation of the primary sequence of the C-terminal cytoplasmic domain of 
Kir6.2 revealed an eight amino acid motif that is not only conserved among Kir6.2 
peptides from a number of species, including rat, mouse, and human (B), but 
also shares striking similarity to a motif in the Nav family of proteins required for 
interaction with ankyrin-G (A).  Kir6.2 peptides were engineered to prematurely 
truncate before (E), or after (D) the Kir6.2 VPIVAEED motif (red box).  (H)  In 
vitro translated peptide lacking this motif was unable to associate with ankyrin-B 
MBD, while (F) in vitro translated full-length Kir6.2 or (G) Kir6.2 truncated 
immediately after VPIVAEED retained the ankyrin-B interaction. 
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 To determine if Kir6.2 residues 316-323 are necessary and sufficient for 
ankyrin-B interaction, a biotinylated peptide against the putative Kir6.2 C-terminal 
ankyrin-binding motif was generated (Figure 18A).   The peptide was engineered 
with an N-terminal biotin and an S-G-S-G linker between the biotin and the 
peptide.   The peptide was coupled to strepavidin beads and incubated with 
purified ankyrin-B MBD.  As displayed in Figure 18B, Kir6.2 residues 316-323 are 
sufficient for ankyrin-B interaction.  Consistent with data using full-length channel, 
a pure peptide generated against the Kir6.2 E322K disease mutant displayed 
significantly reduced ankyrin-binding activity (Figure 18B).  No binding was 
observed with GST alone (or control beads) with either peptide.  Together, these 
results demonstrate that Kir6.2 C-terminal residues 316-323 are necessary and 
sufficient for association with ankyrin-B.   
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Figure 18.  A C-terminal motif in Kir6.2 is sufficient for interaction with 
ankyrin-B. 
 
(A)  Two biotinylated peptides (Kir6.2 WT and Kir6.2 E322K) were synthesized 
for use in an in vitro pulldown experiment.  (B)  While the WT peptide showed 
significant association with GST-ankyrin-B MBD, the E322K mutant peptide 
showed decreased association.  There was no discernable association between 
the peptide and GST alone or with beads alone. 
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A known human PNDM mutation in Kir6.2, E322K, results in loss of 
interaction with ankyrin-B 
 
 A previously identified human variant in the ankyrin-binding motif of Nav1.5 
is associated with human Brugada syndrome arrhythmia (Mohler, Rivolta et al. 
2004) (Figure 19A).  At the cellular level, human Brugada syndrome is 
characterized by decreased Nav1.5 current (Priori, Napolitano et al. 2002).  
Consistent with this phenotype, the Nav1.5 E1053K mutant lacks ankyrin-binding 
activity (Figure 19B) and is not targeted to the membrane of primary adult 
cardiomyocytes (resulting in decreased INa) (Mohler, Rivolta et al. 2004). 
 A human Kir6.2 disease gene mutation that blocks the ankyrin-B/Kir6.2 
interaction was identified.  In 2004, Vaxillaire and colleagues identified a Kir6.2 
gene variant in a three-day-old female with hyperglycemia.  This child was 
insulin-dependent at 10 years, 10 months and characterized with the PNDM 
phenotype (Vaxillaire, Populaire et al. 2004).   Interestingly, this Kir6.2 mutant 
(964G>A leading to E322K) is located in the Kir6.2 ankyrin-binding motif (Figure 
19A).  Moreover, this variant is located in an acidic motif that correlates with the 
Nav1.5 Brugada syndrome disease variant E1053K (also negative to positive 
charge reversal, see Figure 19A).   
 To determine whether the Kir6.2 PNDM disease variant E322K affects 
ankyrin-binding, the human PNDM mutation was generated in the context of full-
length human Kir6.2.  Additionally, Kir6.2 E321K (analogous residue affected in 
Nav1.5 Brugada E1053K mutation) and Kir6.2 D323K were generated (Figure 
19C).  Finally, acidic charges were changed to non-charged alanine residues 
(Kir6.2 E321A, E322A, D323A) in three additional mutants.  Kir6.2 mutants 
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E321K, E322K (PNDM mutation), and D323K nearly abolish ankyrin-B-binding 
activity (Figure 19C).  In contrast, neutral amino acids substitution mutations in 
the Kir6.2 ankyrin-binding motif (E321A, E322A, D323A) had no effect on 
ankyrin-binding (Figure 19C).  These findings identify a key acidic stretch in the 
ankyrin-binding motif as critical for ankyrin-B/Kir6.2 interaction.  More 
significantly, these findings suggest that the human Kir6.2 E322K disease 
mutation disrupts the ankyrin-B/Kir6.2 interaction. 
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Figure 19.  Three charged amino acids within the VPIVAEED motif are 
necessary for interaction with ankyrin-B.   
 
(A)  A known human mutation within the putative ankyrin-B binding motif, E322K, 
is associated with human permanent neonatal diabetes mellitus (PNDM).  
Similarly, a mutation in the Nav family of proteins within the corresponding motif 
results in loss of interaction with ankyrin-G.  (B)  In vitro translated Nav1.5 
E1053K, the mutation which disrupts the Nav1.5/ankyrin-G interaction, is unable 
to associate with ankyrin-G MBD, while wild type Nav1.5 can associate.  (C)  
Kir6.2 constructs containing site-directed mutagenesis of three key charged 
residues (EED) show that interaction with ankyrin-B is lost when any of these 
residues are mutated to the opposite charge, but not when mutated to an alanine 
(note equal loading of Kir6.2 peptides and GST-ankyrin-B MBD).   
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Kir6.2 association is specific to ankyrin-B and not ankyrin-G 
 In order to show that the association of Kir6.2 is specific to ankyrin-B and 
not another member of the ankyrin family, ankyrin-G, in vitro binding analysis 
was used.  Specifically, in vitro translated, radiolabeled Kir6.2 was incubated with 
immobilized GST-tagged ankyrin-B MBD, ankyrin-G MBD, or GST alone.  While 
Kir6.2 shows in vitro association with ankyrin-B MBD, the association with 
ankyrin-G MBD is below that of control (GST alone) (Figure 20).  This is 
consistent with previously published reports which demonstrate that ankyrin gene 
products show specificity for binding partners. 
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Figure 20.  Kir6.2 association is specific to ankyrin-B and not ankyrin-G. 
 
In vitro translated Kir6.2 is able to associate with immobilized GST-ankyrin-B-
MBD, but not GST-ankyrin-G-MBD or GST alone. 
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Ankyrin-B is required for Kir6.2 membrane expression 
 Ankyrin-B is ubiquitously expressed in vertebrate tissues.  Moreover, all 
tested cultured vertebrate heterologous cell lines express ankyrin-B.  Therefore, 
a primary cell culture system lacking ankyrin-B needed to be developed in order 
to test the role of ankyrin-B expression for Kir6.2 membrane targeting.  Primary 
cardiac fibroblasts were isolated from ankyrin-B-/- post-natal day 1 mice (ankyrin-
B-/- mice die shortly after birth (Scotland, Zhou et al. 1998)).  Fibroblasts were 
expanded and the ankyrin-B-/- genotype of the resulting cell culture was 
confirmed by genotyping, immunoblot, and immunostaining (Figure 21A-D).  
Wild-type and ankyrin-B-/- fibroblasts displayed similar properties in culture with 
respect to cell division, growth, size, and morphology.  Immunoblotting of 
fibroblasts also revealed lack of Kir6.2 expression (Figure 21E).  Thus, a primary 
cell system lacking ankyrin-B expression was established.   
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Figure 21.  Ankyrin-B wild type and null cardiac fibroblasts can be isolated 
and expanded in culture.   
 
Cardiac fibroblasts isolated from postnatal day 1 wild type and ankyrin-B null 
mice were verified by (A)  Genotyping (the null mice were engineered with an 
800 bp neocassette disrupting the ANK2 gene), (B)  immunoblotting (note equal 
loading of protein as assayed by NHERF1 expression), and (C)  
immunofluorescence (red staining indicates phalloidin staining, while blue 
staining denotes ToPro staining of genetic material).  Scale bar equals 10 
microns. 
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  A Kir6.2 cDNA tagged with GFP was created to monitor the subcellular 
localization of Kir6.2 in wild type and ankyrin-B-/- fibroblasts.  Kir6.2 was cloned 
from human heart cDNA library and engineered with a C-terminal GFP tag. 
Previously published work demonstrates no significant changes in Kir6.2 
expression or function following the addition of a C-terminal GFP fusion 
{Makhina, 1998 #161; Makhina, 1998 #1619}.  Co-transfection of GFP-Kir6.2 with 
SUR (at 5:1 SUR:Kir6.2 ratio) into wild type fibroblasts revealed GFP-Kir6.2 
fluorescence present at the plasma membrane (Figure 22A, C).  In contrast, 
GFP-Kir6.2 was not efficiently targeted to the membrane of ankyrin-B-/- 
fibroblasts, but instead localized to a perinuclear compartment (Figure 22B, D).   
Together, these findings support a requirement of ankyrin-B expression for Kir6.2 
membrane targeting.    
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Figure 22.  Ankyrin-B is required for Kir6.2 localization in cardiac 
fibroblasts.   
 
(A)  Wild type fibroblasts co-transfected with SUR1 and GFP-Kir6.2 cDNAs show 
diffuse localization of GFP-Kir6.2 (middle panel), distinct from the localization 
pattern of GFP alone (left panel).  Co-transfection with SUR1 and GFP-Kir6.2 
E322K cDNAs shows a perinuclear localization (right panel).  (B)  Ankyrin-B null 
fibroblasts co-transfected with SUR1 and GFP-Kir6.2 show abnormal localization 
of GFP-Kir6.2 (middle panel), which is similar to what is observed with ankyrin-B 
null fibroblasts co-transfected with SUR1 and GFP-Kir6.2 E322K (right panel), 
suggesting a necessary role for ankyrin-B in in vivo localization of Kir6.2.  Red 
corresponds to phalloidin-568 staining. 
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Kir6.2 disease mutant lacking ankyrin-binding activity is not efficiently 
targeted 
 
 Based on the abnormal membrane trafficking of Nav1.5 E1053K disease 
mutation lacking ankyrin-binding activity (Mohler, Rivolta et al. 2004),  the 
membrane targeting of the PNDM Kir6.2 disease mutation, E322K, was 
evaluated.  Site-directed mutagenesis was used to generate full-length GFP-
tagged wild type Kir6.2, E321K, E322K, and D323K.  Wild-type and mutant 
channels were co-transfected with SUR cDNA into HEK293 cells.  Immunoblots 
of co-transfected cells confirmed approximately equal protein expression 
between wild type and mutant cell lines.  As expected, wild type GFP-Kir6.2 was 
primarily localized to the plasma membrane of transfected HEK293 cells 
(compare Figure 23B).   In contrast, Kir6.2 mutants E321K, E322K, and D323K 
were not as efficiently targeted to the plasma membrane (Figure 23C-E).  While 
residual low levels of plasma membrane staining for all of the mutants was 
observed, a significant fraction of the overall GFP-Kir6.2 mutant localization was 
clustered in a peri-nuclear pattern (arrows in Figure 23C-E).   These results 
demonstrate that direct ankyrin-B/Kir6.2 interactions are required for efficient 
Kir6.2 membrane targeting in heterologous HEK293 cells (equivalent to Kir6.2 
loss-of-function).    However, these findings are in stark contrast to the observed 
gain-of-function PNDM phenotype of the human Kir6.2 E322K mutation in vivo 
(Vaxillaire, Populaire et al. 2004). 
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Figure 23.  Interaction with ankyrin-B is necessary for efficient targeting of 
Kir6.2 in HEK293 cells.   
 
(A-E)  HEK293 cells co-transfected with SUR1 and wild type or mutant GFP-
tagged Kir6.2 demonstrates that while wild type GFP-Kir6.2 shows a distinct 
plasma membrane localization (yellow arrows), Kir6.2 mutants that disrupt the 
ankyrin-B/Kir6.2 interaction (E321K, E322K (the human PNDM mutation), and 
D323K) show perinuclear localization (white arrowheads) indicative of inefficient 
targeting.  Red corresponds to phalloidin-568 staining and blue corresponds to 
ToPro staining of nuclear material.  Scale bar equals 10 microns. 
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Kir6.2 mutant lacking ankyrin-binding activity displays decreased ATP 
sensitivity 
 
 In addition to key roles in protein membrane targeting, recent work 
identified an unexpected role for ankyrin polypeptides in regulating ion channel 
biophysical activity {Shirahata, 2006 #1071; Mohler, 2004 #938}.  Moreover, the 
dependence of ankyrin-pathways for ion channel targeting in cultured 
heterologous cell systems and vertebrate tissues are cell-type specific.   In fact, 
these differential trafficking systems (ankyrin-dependent vs. ankyrin-independent) 
have enabled the study of the effect of ankyrin activity on channel biophysics in 
the absence of competing membrane trafficking defects {Shirahata, 2006 #1071; 
Mohler, 2004 #938}.  Using confocal imaging of transfected heterologous cell 
lines, a number of cell lines were tested to identify a system to analyze the 
biophysical function of GFP-Kir6.2 E322K at the plasma membrane.  After testing 
a number of lines (HEK293, CHO, NIH3T3), COSm6 cells were determined to 
most efficiently target Kir6.2 E322K to the plasma membrane (although trafficking 
is still impaired by ~20%, see Figure 24A-C).  Interestingly, these same cells 
have been widely used to study Kir6.2 mutant function as they lack endogenous 
Kir6.2 expression (Pinney, MacMullen et al. 2008) (Figure 24E), yet they do 
express endogenous ankyrin-B (Figure 24D).  In agreement with the previous 
imaging studies, COSm6 cells expressing GFP-Kir6.2 and GFP-Kir6.2 E322K 
demonstrated only a mild reduction in Kir6.2 membrane levels (under metabolic 
inhibition conditions; cells stably express SUR1; as assessed by Rb+ flux assays 
(Figure 24B, C).   Thus, the COSm6 cell line provides a suitable system for the 
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analysis of Kir6.2 membrane function without the interfering defects associated 
with ankyrin-mediated targeting. 
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Figure 24.  COSm6 cells demonstrate significant plasma membrane 
expression of E322K Kir6.2-GFP. 
   
(A)  While GFP-Kir6.2 shows significant plasma membrane localization in 
COSm6 cells, the GFP-Kir6.2 E322K mutant also demonstrates plasma 
membrane localization, though reduced.  Rubidium flux analysis (under 
metabolic inhibition with (C) or without (B) glibenclamide administration) 
demonstrated that the surface expression of GFP-Kir6.2 E322K is reduced by 
~15% as compared with wild type.  Thus, the COSm6 cell line provides a cell 
model system to evaluate Kir6.2 E322K function independently of defects in 
ankyrin-B-dependent targeting.  Nuclei are stained blue.  (D)  COSm6 cells 
express endogenous ankyrin-B, but no endogenous Kir6.2.  Blue corresponds to 
ToPro staining of nuclear material.  Scale bar equals 10 microns. 
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 Transfected COSm6 cells were utilized to test the potential role of ankyrin-
B/Kir6.2 membrane function independent of a targeting phenotype.  Single-
channel ATP sensitivity experiments were performed for the wild type and mutant 
channel.  As shown in Figure 25B, the Kir6.2 E322K channel displays a 
significant reduction in ATP sensitivity compared with the wild type channel 
(Figure 25A).  Specifically, the mutant channel that lacks ankyrin-B-binding 
activity is much less sensitive to ATP, as indicated by a shift in the K1/2 for ATP 
binding from 15 µM in wild type to 62 µM in the mutant (Figure 25C).  These data 
are consistent with E322K as a Kir6.2 gain-of-function mutation, and are 
consistent with the insulin-dependent gain-of-function clinical phenotype of this 
channel mutation in the human population.   
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Figure 25.  The Kir6.2 E322K mutant demonstrates reduced ATP sensitivity.   
 
(A)  Wild type Kir6.2 demonstrates ATP sensitivity where most channels are 
closed at 100 µM ATP, whereas, (B)  Kir6.2 E322K demonstrates a significant 
reduction in ATP sensitivity, indicated by most channels remaining open at 100 
µM ATP.  (C)  When K1/2 values are calculated, Kir6.2 E322K demonstrates a 
rightward shift in ATP sensitivity (62 µM) as compared with wild type ATP 
sensitivity (15 µM). 
 
 
 
 
 
 
 106
ATP sensitivity of Kir6.2 can be modulated using a competing peptide 
  In order to more fully explore the role of ankyrin-B in the regulation of 
Kir6.2 metabolic regulation, two unique peptides were designed for a competition 
assay.  Specifically, one peptide (WT peptide) corresponds to the ankyrin-B 
binding motif of Kir6.2 (VPIVAEED) while the second contains the PNDM 
mutation (VPIVAEKD).  The WT peptide, in theory, should compete off the 
endogenous ankyrin-B/Kir6.2 interaction.  COSm6 cells co-transfected with 
SUR1 and wild type Kir6.2-GFP were assayed for ATP sensitivity in the presence 
and absence of each peptide.  Figure 26A demonstrates that the addition of the 
WT peptide reduces the ATP sensitivity of wild type Kir6.2, while the mutant 
peptide had no effect.  As a control, these two peptides were used in an ATP 
sensitivity assay with COSm6 cells co-transfected with SUR1 and E322K Kir6.2-
GFP.  These results demonstrate no effect of either peptide (Figure 26B).  
Together, these data suggest a role for ankyrin-B in the metabolic regulation of 
the Kir6.2 subunit of the KATP channel. 
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Figure 26.    ATP sensitivity can be modulated using a competing peptide. 
 
(A)  Administration of WT peptide, corresponding to the ankyrin-B-binding motif 
of Kir6.2, results in a significant decrease in KATP channel ATP sensitivity, while 
administration of the MUT peptide has no effect.   (B)  Neither peptide has an 
effect on E322K-containing KATP channel ATP sensitivity. 
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Discussion  
 Ankyrin-B is necessary for the trafficking of a number of ion channels, 
transporters, and pumps to distinct microdomains of cellular membranes.  
Numerous studies have demonstrated the necessity of this targeting pathway, 
with significant alterations in cellular function resulting when ankyrin-B is 
removed or mutated (Mohler, Schott et al. 2003; Mohler, Splawski et al. 2004; 
Mohler, Davis et al. 2005; Mohler, Healy et al. 2007).  The role of ankyrin-B-
mediated pathways in excitable cells, like neurons and cardiomyocytes, has been 
well-established and can be applicable to an excitable cell like the pancreatic 
beta cell.  In addition, a number of known ankyrin-B binding partners are present 
in the pancreatic beta cell; namely, the NKA, NCX1 exchanger, and the InsP3 
receptor.  The discovery of ankyrin-B expression in the pancreas lays the 
foundation for studies as to the role of ankyrin polypeptides in beta cell function 
and, possibly, human disease.   
 The KATP channel is a critical component of the beta cell membrane, with 
severe dysfunction resulting from the loss of KATP channel subunits or mutations 
in KATP channel genes.   The unexpected observation that Kir6.2 expression is 
significantly decreased in heart and pancreatic lysates from ankyrin-B+/- mice led 
to in vitro binding analyses which confirmed a direct interaction between ankyrin-
B MBD and the C-terminal cytosolic domain of Kir6.2.  Referring to previously 
published data regarding the ankyrin-G binding domain of Nav1.5, a conserved 
eight amino acid motif was found to be both necessary and sufficient for ankyrin-
B association with Kir6.2.  Perhaps most exciting about these observations is the 
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realization that a known human PNDM mutation, E322K, resides in this eight 
amino acid motif.  My data further implicate three charged amino acids, E321, 
E322, D323 as necessary for interaction with ankyrin-B MBD.  Furthermore, 
mutation of these residues to an opposite charge results in significant loss of 
plasma membrane localization of Kir6.2 in HEK293 cells, indicating a necessary 
role for ankyrin-B in Kir6.2 targeting in vivo.   Finally, the E322K mutation 
demonstrates a significant reduction in ATP sensitivity.  Preliminary data suggest 
that it may be the association with ankyrin-B which confers ATP sensitivity to the 
Kir6.2 subunit of the KATP channel.  However, future work is required to validate 
the role of ankyrin-B in KATP channel metabolic regulation. 
 Three-dimensional evaluation of the Kir6.2 protein reveals that the 
ankyrin-B binding motif protrudes from the protein in a finger-like projection.  
Such presentation may be necessary for ankyrin-B association (Figure 27).  
Close evaluation of a similar site on Kir6.1, which does not demonstrate an in 
vivo association with ankyrin-B (Figure 14) reveals that Kir6.1 lacks a central 
proline residue that is present in the ankyrin-B-binding motif of Kir6.2 (VPIVAEED 
versus TSYIAEEI).  Perhaps this proline provides for the three-dimensional 
structure of the binding motif, allowing presentation of this region of Kir6.2 to 
ankyrin-B.  Likewise, the absence of the third negatively-charged amino acid may 
play a key role in the absence of Kir6.1/ankyrin-B association.  It will be 
interesting to evaluate the crystal structure of Kir6.1, which is currently unknown, 
in order to determine whether this protrusion is present. 
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Figure 27.  The ankyrin-B-binding motif of Kir6.2 resides on the outside of 
the Kir6.2 subunit. 
 
The ankyrin-B-binding motif of Kir6.2 protrudes out from the Kir6.2 polypeptide, 
providing an easily accessible region to the cytosolic ankyrin-B.  Reprinted by 
permission from Macmillan Publishers Ltd:  EMBO Rep 6(5):470-5, copyright 
2005 (Proks, Girard et al. 2005). 
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 Dual targeting and ATP sensitivity cellular phenotypes and human 
disease.  The current findings of this study illustrate that the Kir6.2 E322K 
mutation is associated with two molecular phenotypes: 1) reduced channel 
membrane targeting (loss-of-function) and 2) decreased ATP sensitivity (gain-of-
function).  Interestingly, these two defects would be expected to have opposite 
effects on IKATP and therefore beta cell excitability.  Based on the link between the 
Kir6.2 E322K and human permanent neonatal diabetes (typically IKATP gain-of-
function), I hypothesized that decreased ATP sensitivity represented the primary 
cellular phenotype resulting in disease. To test this prediction, I used 
mathematical modeling and computer simulation to determine the effect of 
altered ATP sensitivity associated with the Kir6.2 E322K mutation on beta cell 
excitability.  An established model of the pancreatic beta cell was modified 
(Fridlyand, Tamarina et al. 2003) to investigate the effect of reduced ATP 
sensitivity on beta cell firing rate (Figure 28A).  ATP sensitivity is accounted for in 
the model as the fraction of open ATP channels, OKATP (See Equation 1 in 
Methods and Experimental Approach).  OKATP for the control KATP channel (WT, 
black line) and the E322K mutant (blue line) was fit to my measured data in 
COSm6 cells (Figure 28B).  OKATP for the heterozygous tetrameric channel 
(WT/E322K to mimic human phenotype, red line) was calculated to be 25 µM 
based on the fact that Kir6.2 subunits exert an additive effect on the open state 
probability of the tetrameric channel (Craig, Ashcroft et al. 2008), as described in 
the Methods section.  Surprisingly, introducing the effect of the heterozygous 
E322K mutation on OKATP into the beta cell model completely eliminates 
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spontaneous membrane depolarization (Figure 28C).  Unexpectedly, these 
electrical findings are inconsistent (significantly too severe) with the observed 
human E322K phenotype, which requires a much lower dose of insulin to 
maintain glucose homeostasis as compared with individuals harboring other 
gain-of-function mutations in Kir6.2, suggesting a much more moderate effect of 
the E322K mutation on beta cell activity (Vaxillaire, Populaire et al. 2004). 
  Next, the effect of abnormal Kir6.2 E322K trafficking on beta cell 
excitability and membrane depolarization was analyzed.  IKATP conductance was 
reduced to 85% or 60% of its control value, to simulate changes observed in 
COSm6 and HEK293 cells, respectively (Figure 28D).  Surprisingly, reducing 
IKATP conductance even to 60% of its control value only slightly increased the rate 
of spontaneous membrane depolarization (Figure 28D).  Again, these 
phenotypes were inconsistent with the observed human Kir6.2 E322K 
phenotype.   
 Finally, the dual phenotypes observed in the study were modeled.  The 
revised model, including both trafficking defects along with reduced ATP 
sensitivity, produces a net decrease in cell excitability more consistent with the 
observed human E322K phenotype (moderate insulin dependence) due to a net 
increase in IKATP (Figure 28E).  Specifically, there was a 29% decrease in the 
bursting period of the E322K heterozygous mutant compared to WT (76 ms and 
98 ms, respectively) (Figure 28E).  These results suggest that, while the ATP 
sensitivity represents the dominant cellular phenotype resulting in PNDM, the 
reduction in IKATP conductance due to reduced membrane channels (abnormal 
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trafficking) acts to protect the beta cell from the elimination of action potential 
firing.     
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Figure 28.  Dual targeting and ATP sensitivity cellular phenotypes and 
human disease. 
 
(A)  Schematic of the mouse pancreatic beta cell mathematical model and 
simulated spontaneous oscillations in transmembrane potential (right, top) and 
IKATP (right, bottom).  (B)  ATP dependence of the open probability (OKATP) for 
control (WT, black line) and E322K mutant (blue line) KATP channels fit to my 
measured data in COSm6 cells (closed circles; data presented in Figure 26).  
OKATP for simulated E322K heterozygous mutant channel (WT/E322K, red line) is 
also shown).  (C)  Steady-state transmembrane potential in control model (black 
line) and with OKATP corresponding to the heterozygous E322K KATP channel (red 
line).  While the control model shows spontaneous oscillations in transmembrane 
potential, the heterozygous model is completely inexcitable.  (D)  Spontaneous 
oscillations in transmembrane potential are shown for the control model (WT, 
black line), and with IKATP conductance reduced to 85% (red line) or 60% (blue 
line) of control value to simulate changes observed in COSm6 and HEK293 cells, 
respectively (original data presented in Figures).  Reducing IKATP conductance 
produces a slight increase in the rate of spontaneous membrane depolarization 
due to a loss of repolarizing current.  (E)  Simulated spontaneous oscillations in 
transmembrane potential in the control (WT, black line) and E322K heterozygous 
mutant (red line), including both defects in KATP channel trafficking and ATP 
sensitivity.  Notice that while the spontaneous firing rate of the heterozygous 
mutant cell is dramatically slower than WT, the cell remains excitable. 
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CHAPTER V 
 
THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR AND LOCAL CALCIUM 
SIGNALING 
 
Introduction 
 A very steep gradient of Ca2+ (roughly four orders of magnitude) exists 
across the plasma membrane of all eukaryotic cells; specifically, cytosolic free 
calcium is maintained at 100 nM, while the extracellular milieu generally has a 
Ca2+ concentration over 1 mM (Mikoshiba 2007).  This gradient is necessary for 
cellular survival, considering the cytotoxic consequences of high concentrations 
of intracellular Ca2+.   In contrast, the highly-choreographed release of Ca2+ from 
the ER/SR into distinct cellular microdomains allows for an array of cellular 
functions:  fertilization, embryonic pattern formation, cell differentiation and 
proliferation, transcription factor activation, synaptic function, cardiac contractility, 
and apoptosis (Streb, Irvine et al. 1983; Furuichi, Yoshikawa et al. 1989; Berridge 
1993; Furuichi, Kohda et al. 1994).  This versatility in function lies in the speed, 
amplitude, and spatio-temporal patterning of Ca2+ signaling.  In order to generate 
this versatility, the cell has several calcium-handling ion channels, transporters, 
and pumps at its disposal. 
 InsP3 receptors are calcium-release channels found in the ER/SR 
membrane of diverse cell types.  Specifically, calcium release from these 
intracellular stores is activated by InsP3, a second messenger produced via the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2).  InsP3 is produced in 
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response to a number of extracellular stimuli, including hormones, growth factors, 
and neurotransmitters. Binding of InsP3 to InsP3 receptors increases InsP3 
receptor calcium sensitivity and, in a biphasic manner, induces a stimulatory 
effect at low calcium concentrations and an inhibitory effect at higher calcium 
concentrations (Taylor and Laude 2002).   InsP3 receptor-induced release of 
calcium from intracellular stores provides positive feedback whereby calcium 
amplifies its own release.   
 
InsP3 Receptor Structure and Regulation 
 The functional InsP3 receptor complex exists as a homo- or hetero-
tetramer of 260 kD InsP3 receptor subunits.  Three distinct isoforms (types I, II, 
and III) have been cloned (Furuichi, Yoshikawa et al. 1989; Mignery, Sudhof et 
al. 1989; Sudhof, Newton et al. 1991; Blondel, Takeda et al. 1993; Maranto 1994; 
Morgan, De Smedt et al. 1996) with isoform expression varying with cell type and 
with isoform-specific functions (Perez, Ramos-Franco et al. 1997).  Cerebellar 
Purkinje cells, for example, express InsP3 receptor type I almost exclusively 
(Wojcikiewicz 1995), while pancreatic acinar cells express types II and III (Bush, 
Stuart et al. 1994), and many epithelia express all three isoforms (Bush, Stuart et 
al. 1994; Nathanson, Fallon et al. 1994; Wojcikiewicz 1995).  The formation of 
hetero-tetramers, due to the association of different isoform subunits, allows an 
additional level of receptor diversity (Joseph, Lin et al. 1995; Monkawa, Miyawaki 
et al. 1995; Onoue, Tanaka et al. 2000). 
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 The three isoforms share a similar domain structure.  Types II and III InsP3 
receptors have an overall sequence homology with type I InsP3 receptor of 69% 
and 64%, respectively (Sudhof, Newton et al. 1991; Blondel, Takeda et al. 1993).  
However, the three isoforms possess different affinities for InsP3 (type II > type I 
> type III) (Sudhof, Newton et al. 1991; Maranto 1994; Newton, Mignery et al. 
1994).  Each isoform contains a large regulatory domain between the N-terminal 
InsP3 binding site and the C-terminal pore-forming region (Figure 29A).  The 
pore-forming region contains six transmembrane domains (Figure 29B), which is 
where many intracellular compounds exert their modulatory effects (Patel, 
Joseph et al. 1999).  The regulatory domain has several Ca2+ binding sites, as 
well as specific binding sites for ATP (Maeda, Kawasaki et al. 1991).  Additional 
regulatory control of the InsP3 receptor is via associated proteins (Thrower, Lea 
et al. 1998; MacKrill 1999), which permit a wide range of responses that are 
observed for InsP3 receptor-induced Ca2+ release.  Finally, phosphorylation 
status of the InsP3 receptor also affects the properties of Ca2+ signaling (LeBeau, 
Yule et al. 1999).  Pancreatic cells, for example, display different Ca2+ responses 
depending on the agonist.  Specifically, cholecystokinin causes rapid 
phosphorylation of InsP3 receptors, while acetylcholine does not produce such a 
response (LeBeau, Yule et al. 1999).  
 
InsP3 Receptors Form Macromolecular Signaling Complexes 
 The expression, localization, and function of the InsP3 receptors are 
regulated by various cellular proteins (Figure 30).  Cytochrome c (Boehning, 
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Patterson et al. 2003) and huntingtin (Htt)-associated protein-1A (HAP1A) (Tang, 
Tu et al. 2003; Bezprozvanny and Hayden 2004) were found to bind to the C-
terminal region.  Interestingly, InsP3 receptor I activation by InsP3 is sensitized by 
the polyglutamine (polyQ) expansion of Htt caused by Huntington disease.  
Protein phosphatases PPI and PP2A (DeSouza, Reiken et al. 2002; Tang, Tu et 
al. 2003), receptor for activated C-kinase 1 (RACK1) (Patterson, van Rossum et 
al. 2004), and chromogramin (Yoo 2000) have also been reported to bind to the 
channel region and regulate channel activity.  Carbonic anhydrase-related 
protein (CARP) has been found to bind to a central part between the InsP3 
binding core and the channel region to regulate channel activity (Hirota, Ando et 
al. 2003).  Homer binds to the N-terminal suppressor region (Tu, Xiao et al. 
1998), possibly orchestrating the association of InsP3 receptors to group 1 
metabotropic glutamate receptors (mGluR1), forming mutimeric, junctional Ca2+ 
signaling networks in cerebellar Purkinje cells (Sandona, Scolari et al. 2003). 
 The discovery of numerous binding partners suggests that the InsP3 
receptor forms a macromolecular signaling complex and functions as the center 
of multiple signaling cascades.  The diversity of Ca2+ signaling patterns, as well 
as the subcellular distribution of InsP3 receptors, is very likely influenced by the 
components of the InsP3 receptor signaling complex, which can differ between 
cell types and even between distinct subcellular spaces. 
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Figure 29.  Domain organization of the InsP3 receptor 
 
(A)  InsP3 receptor isoforms have three general domains:  an N-terminal InsP3-
binding domain, a central regulatory domain, and a C-terminal 
transmembrane/channel-forming domain.  (B) The InsP3 receptor localizes in the 
ER/SR membrane via six transmembrane domains.  Both the N- and C-termini 
reside in the cytoplasm. 
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Figure 30.  A representative collection of InsP3 receptor binding partners. 
The InsP3 receptor has a host of protein binding partners that are involved in the 
targeting and regulation of channel activity. 
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InsP3 Receptor Function in Excitable Cells 
 Beta cells.  Stimulation by several neurotransmitters, growth factors, 
metabolites, and hormones have been reported to result in an increase in 
intracellular Ca2+ concentration by enhancing the turnover of phosphoinositides 
(Berridge, Heslop et al. 1984).  InsP3 opens the InsP3 receptor on the ER, 
releases Ca2+ from the lumenal store, and produces an increase in cytosolic 
Ca2+.  Exposure of isolated rat pancreatic islets to high levels of glucose has 
three important effects with regard to InsP3 receptor-mediated activity.  First, 
exposure to glucose rapidly increases the transcription and expression of the 
type III InsP3 receptor in beta cells (Lee, Jonas et al. 1999).  Second, the 
exposure to glucose enhances the incorporation of palmitate into phospholipids 
(Berne 1975).  Glucose and other secretagogues not only stimulate phospholipid 
biosynthesis directly, but also supply one of the metabolic precursors for 
phospholipid biosynthesis:  glycerol-3-phosphate.  Enhanced phospholipid 
synthesis results in the generation of PIP2, which can be cleaved by 
phospholipase C (PLC) into diacylglycerol (DAG) and InsP3.  Finally, rapid 
increases in InsP3 occur following PIP2 hydrolysis in islets in response to glucose 
(Biden, Peter-Riesch et al. 1987).  Therefore, glucose increases the expression 
of type III InsP3 receptor, the InsP3-generating capability of beta cells, and also 
the production of InsP3 by the beta cell, each occurring in a time-specific manner.  
Ultimately, these effects promote insulin secretion by increasing the intracellular 
Ca2+ concentration. 
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 Considering that modulators of insulin secretion, especially second 
messengers like InsP3, can affect intracellular Ca2+ directly, it can easily be 
appreciated that alterations in these secondary messengers can lead to altered 
insulin secretion.  While the production of ATP via glycolysis and the citric acid 
cycle results in stimulus-secretion coupling by the beta cell, high concentrations 
of ATP can inhibit InsP3-induced Ca2+ release by the type I InsP3 receptor 
(Bezprozvanny and Ehrlich 1993), producing significant alterations in intracellular 
Ca2+, and possibly defects in insulin secretion.  Likewise, Ca2+ can regulate its 
own release by the type I InsP3 receptor (Bezprozvanny, Watras et al. 1991).  As 
a result, both ATP and Ca2+ play vital roles with regards to InsP3 receptor-
mediated Ca2+ release and insulin secretion by the beta cell. 
 Cardiomyocytes.  InsP3 receptors play crucial roles in regulating a 
diverse array of cardiac functions.  Strategic localization of InsP3 receptors in 
cytoplasmic compartments and the nucleus enables them to participate in 
subsarcolemmal, bulk cytoplasmic, and nuclear Ca2+ signaling in embryonic stem 
cell-derived and neonatal cardiomyocytes, and in adult cardiac myocytes from 
the atria and ventricles.  Specifically, atrial InsP3 receptors are involved in the 
increase in contractility due to elevated Ca2+ transients (Vites and Pappano 
1995), while the dyadic localization of InsP3 receptors, where excitation-
contraction coupling is initiated, in the ventricular myocytes boosts the amplitude 
of systolic Ca2+ transients (Domeier, Zima et al. 2008).  Cardiac nuclear InsP3 
receptors are involved in the activation of nuclear Ca2+/calmodulin-dependent 
 123
protein kinase II (CaMKIIδB) to promote phosphorylation of histone deacetylase 
(HDACs) and, therefore, transcription (Wu, Zhang, et al.  2006).   
 Interestingly, expression of InsP3 receptors is altered in cardiac disease 
such as atrial fibrillation (Kaplan, Jurkovicova et al. 2007), arrhythmias 
(Woodcock, Arthur et al. 2000; Mohler, Schott et al. 2003), diabetic 
cardiomyopathy (Guner, Arioglu et al. 2004; Zhou, Hu et al. 2006), hypertrophy 
(Berridge 2003) and heart failure (Go, Moschella et al. 1995), suggesting the 
involvement of InsP3 signaling in the pathology of these diseases.  Thus, InsP3 
receptors play important physiological and pathological functions in the heart, 
ranging from the regulation of pacemaking, excitation-contraction, and excitation-
transcription coupling to the initiation and/or progression of arrhythmias, 
hypertrophy, and heart failure. 
  
Diseases Associated with InsP3 Receptors and InsP3 Receptor-mediated 
Signaling 
 
 InsP3 is an important second messenger that mediates the effects of many 
neurotransmitters and hormones.  Consequently, changes in the level of InsP3, 
either as a result of altered synthesis or abnormal metabolism, will influence 
InsP3 receptor gating and may be expected to have profound physiological 
effects.  Manipulation of InsP3 levels may also provide a therapeutic target for 
disease in which neurotransmitters that elevate InsP3, or the receptors for these 
transmitters, are affected. 
 The opisthotonos mouse.  No human disease associated with mutations 
in any of the genes encoding InsP3 receptor have been identified, but a number 
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of naturally-occurring mutations in mice produce disease.  The opisthotonos (opt) 
mouse, which has a deletion in the InsP3 receptor I gene, displays epileptic-like 
activity (Street, Bosma et al. 1997).   A less severe, but similar, ataxic phenotype 
is observed in the mutant mice staggerer, nervous, and Purkinje-cell 
degeneration, which express low levels of InsP3 receptor I.  In addition, mice in 
which the InsP3 receptor I gene has been knocked-out either die in utero or 
exhibit ataxia and epileptic seizures at about nine days after birth and die before 
weaning (Matsumoto, Nakagawa et al. 1996).  Thus, InsP3 receptor I is essential 
for normal brain function, which may explain why this type of mutation is not seen 
in the human population, as such individuals would probably not survive in utero. 
  Manic depression and lithium treatment.  Manic depression is 
characterized by dramatic mood swings between mania and depression and can 
be controlled effectively with the carefully-monitored administration of lithium.  It 
has been argued that the therapeutic effects of lithium result from its potent 
inhibitory effect on inositol phosphate metabolism (Berridge, Downes et al. 1989).  
Inhibition of inositol monophosphate phosphatase by lithium will cause depletion 
of inositol and reduce the synthesis of inositol lipids required for formation of 
InsP3.  Inositol depletion will be particularly significant in those cells which are 
unable to replenish inositol by uptake from external sources; this is the case for 
brain neurons where the inositol supply is limited by the blood-brain barrier.  By 
blocking the supply of inositol, lithium will impair InsP3 generation in response to 
neurotransmitters and dampen the effects of receptor hyperactivity, which is 
thought to be responsible for the mood swings found in manic depression.  
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 Lowe’s oculocerebrorenal syndrome.  Lowe’s oculocerebrorenal 
syndrome is an X-linked disease which affects the kidneys, the brain, and the 
lens of the eye (Attree, Olivos et al. 1992).  Patients exhibit profound mental 
retardation, blindness as a result of cataracts, glaucoma, and microphthalmos 
(small eyes) (Attree, Olivos et al. 1992).  The renal defect manifests principally as 
proteinuria and rickets.  Lowe’s oculocerebrorenal syndrome is not caused by 
mutations in the InsP3 receptor itself, but instead results from defective regulation 
of Ca2+ release due to impairment of InsP3 metabolism.  The gene responsible for 
this disease is located on the long arm of chromosome X and encodes a 112 kD 
protein with 71% similarity to the human inositol polyphosphate-5-phosphatase 
(Attree, Olivos et al. 1992).  This suggests that the protein may be a related 
phosphatase and thus also involved in the metabolism of InsP3.  It is expressed 
in the brain, skeletal muscle, heart, kidney, lung, and placenta.  The loss of the 
functional protein is expected to lead to the elevation of cytosolic InsP3, and 
therefore an increase in intracellular Ca2+, which could account for the profoundly 
deleterious effects associated with the loss of this protein phosphatase. 
 
Summary 
 The InsP3 receptor is an ER/SR signaling center that forms a 
macromolecular signaling complex based on its scaffolding properties.  
Biochemical and biophysical evaluation of the molecular properties of InsP3 
receptors have led to the discovery of various mechanisms that contribute to the 
fine-tuning of InsP3 receptor-mediated Ca2+ signals.  These mechanisms underlie 
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the assembly of InsP3 receptor-associated molecules in addition to the 
subcellular localization of the signal.  The discovery of numerous binding 
partners suggests that the InsP3 receptor forms a macromolecular signaling 
complex that can function as a center of multiple local signaling cascades.  The 
diversity of Ca2+ signaling patterns, as well as the subcellular distribution 
mechanism of InsP3 receptors, is most likely a product of the members of the 
InsP3 receptor-signaling complex, which differs from cell to cell and subcellular 
space to subcellular space. 
 While no known human mutations in any of the InsP3 receptor genes have 
been reported, modulation of the molecules which regulate InsP3 receptor 
localization and activity result in significant alterations in cellular physiology.  
Loss of InsP3 receptor localization in the cardiomyocyte SR as a result of loss of 
ankyrin-B expression, contributes to severe dysfunction in intracellular Ca2+ 
dynamics, resulting in an increased risk of sudden cardiac death (Mohler, Davis 
et al. 2003).  Likewise, a reduction in the generation of intracellular InsP3 has 
been associated with mental retardation, blindness, glaucoma, microphthalmos, 
and proteinuria.  Therapeutic modulation of InsP3 production via the 
administration of lithium has been used as an effective treatment for manic-
depression.  Future studies to determine the roles of other InsP3 receptor binding 
partners will likely provide vital clues to the modulation and targeting of InsP3 
receptors in vivo. 
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CHAPTER VI 
 
ANKYRIN-B INTERACTS WITH A CYTOPLASMIC N-TERMINAL REGION OF 
THE InsP3 RECEPTOR 
 
   
   
Introduction 
 
 In 1993, two independent groups identified an interaction between the 
InsP3 receptor and the adaptor protein ankyrin (Bourguignon, Jin et al. 1993; 
Joseph and Samanta 1993).  Specifically, Joseph and colleagues demonstrated 
that the InsP3 receptor co-immunoprecipitated with ankyrin-R from brain (Joseph 
and Samanta 1993).  Moreover, Bourguignon and colleagues showed that 
ankyrin-R and InsP3 receptor co-purified from murine T-lymphoma cells 
(Bourguignon and Jin 1995), interacted directly with high affinity, and that 
ankyrin-R inhibited InsP3-binding and InsP3-dependent radiolabeled calcium flux 
(Bourguignon, Iida et al. 1993; Bourguignon, Jin et al. 1993).  Over the past 
fifteen years, a number of groups have replicated ankyrin/InsP3 receptor 
interactions using purified proteins, co-immunoprecipitation assays, 3[H]-InsP3 
binding experiments, and pulse-chase biosynthesis experiments (Feng and 
Kraus-Friedmann 1993; Tuvia, Buhusi et al. 1999; Hayashi, Maurice et al. 2000; 
Hayashi and Su 2001; Mohler, Schott et al. 2003; Mohler, Davis et al. 2004; 
Mohler, Splawski et al. 2004; Mohler, Davis et al. 2005; Liu, Miyakawa et al. 
2007).    Additional evidence for the relevance of the ankyrin/InsP3 receptor 
interaction comes from mouse models with reduced ankyrin-B expression that 
display significant defects in InsP3 receptor expression, subcellular localization, 
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and decreased InsP3 receptor post-translational stability (Mohler, Davis et al. 
2004). 
 Multiple independent studies have documented in vitro and in vivo 
interactions between ankyrin polypeptides and the InsP3 receptor.  Moreover, 
loss of ankyrin-B leads to loss of InsP3 receptor membrane expression and 
stability in cardiomyocytes.  Despite extensive biochemical and functional data, 
the validity of in vivo ankyrin/InsP3 receptor interactions remains controversial.  
This controversy is based on inconsistencies between a previously-identified 
ankyrin-binding region on the InsP3 receptor and InsP3 receptor topology data 
that demonstrate the inaccessibility of this lumenal binding site on the InsP3 
receptor to cytosolic ankyrin polypeptides.  Despite overwhelming evidence 
supporting the ankyrin/InsP3 receptor interaction, questions remain as to the 
validity of the interaction based on InsP3 receptor structural mapping data 
performed nearly a dozen years ago (Bourguignon and Jin 1995).  In 1995, an 11 
residue motif in the InsP3 receptor (GGVGDVLRKPS, Figure 31A-B) was 
identified as the binding site for ankyrin (Bourguignon and Jin 1995).  This site 
(2548-2558 on rat InsP3 receptor I) corresponded to a site of amino acid similarity 
to the ankyrin-binding site on CD44 ((Bourguignon and Jin 1995), see Figure 
31B).   Furthermore, a peptide corresponding to this sequence competed 
ankyrin/InsP3 receptor interactions and blocked ankyrin-induced inhibitory effects 
on InsP3 binding and InsP3-dependent calcium release events (Bourguignon and 
Jin 1995).  These data were reported before the topology of the InsP3 receptor 
was resolved, and the authors speculated that the predicted binding site resided 
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in the cytosol, consistent with the localization of cytoplasmic ankyrin 
(Bourguignon and Jin 1995).   Several groups have since determined the 
membrane topology of the InsP3 receptor, indicating that residues 2548-2558 
reside in the ER lumen (see arrow in Figure 31A) and are, therefore, unable to 
interact with cytosolic ankyrin polypeptides.  Subsequently, despite compelling 
biochemical and animal findings, both ankyrin and InsP3 receptor fields remain 
unclear regarding the feasibility of in vivo ankyrin/InsP3 receptor interactions (see 
comments in (Patel, Joseph et al. 1999; Roderick and Bootman 2003; Mohler, 
Davis et al. 2004; Patterson, Boehning et al. 2004; Vermassen, Parys et al. 2004; 
Foskett, White et al. 2007)).   
 Here, two approaches were used to revisit the structural requirements for 
ankyrin-binding on the InsP3 receptor.  Using yeast two-hybrid and in vitro binding 
experiments, I was able to map the ankyrin-binding region on the InsP3 receptor 
type I to residues 955-991 (Kline, Cunha et al. 2008).  Based on the membrane 
topology of the InsP3 receptor, these data demonstrate that the ankyrin-binding 
region is located on the cytoplasmic face of the receptor, validating the feasibility 
of the in vivo ankyrin/InsP3 receptor interactions.   
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Figure 31.  Putative ankyrin-B-binding site on the InsP3 receptor.   
 
(A)  Domain organization of the InsP3 receptor monomer, depicting membrane 
topology, cytoplasmic and lumenal protein orientation, and the previously 
proposed ankyrin-binding motif in the C-terminal domain.  (B)  Putative ankyrin-
binding site in InsP3 receptor identified by sequence similarity with CD44 ankyrin-
binding motif.  Minimal ankyrin-binding residues on CD44 (Bourguignon and Jin 
1995) are presented.  Amino acid sequences below CD44 denote sequence 
homology of residues in InsP3 receptor C-terminus and the CD44 sequence.  
Reprinted with permission of Wiley-Liss, Inc. a subsidiary of John Wiley & Sons, 
Inc.  Kline, et al.  “Revisiting Ankyrin-InsP3 Receptor Interactions:  Ankyrin-B 
Associates with the Cytoplasmic N-Terminus of the InsP3 Receptor.”  J Cell 
Biochem 104(4):1244-53 copyright 2008 by John Wiley & Sons, Inc. (Kline, et al. 
2008). 
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Methods and Experimental Approach 
 Design of InsP3 receptor constructs.  InsP3 receptor constructs were 
engineered into pACT2 (Clontech) for yeast two-hybrid assays using standard 
molecular techniques and full-length rat InsP3 receptor I as the template.  InsP3 
receptor constructs were also engineered into pcDNA3.1(+) for in vitro translation 
experiments.  Positive clones were confirmed by restriction digestion and 
sequencing.  For all in vitro translated constructs, an initiator methionine was 
introduced at the beginning of the coding sequence to facilitate translation.  InsP3 
receptor constructs were designed based on trypsin proteolysis mapping 
(Yoshikawa, Iwasaki et al. 1999) to preserve major folding domains in the binding 
assays.  Due to the large size of the cytoplasmic N-terminus, this region was 
subdivided into seven fragments. 
 Design of ankyrin-B constructs.  The MBD, plus residues of the SBD, of 
human 220 kD ankyrin-B (amino acids 1-958) were cloned into pGEX-6P1 
(Amersham Biosciences) for expression as a GST-fusion protein (C-terminal 
GST).  Protein expression was carried out in BL21(DE3)pLysS (Promega) 
competent cells and purified using glutathione-sepharose. 
 Full-length InsP3 receptor production.  InsP3 receptor constructs 
lacking amino acids 924-991 were generated using baculovirus.  Full-length wild 
type or mutant cDNAs were co-expressed in a standard transfection vector 
(Clontech) with Bsu36I-digested BacPAK6 viral DNA into Spondoptera frugiperda 
cells (Sf21 cells, Clontech) using the BacPAK Baculovirus Expression System 
(Clontech).  Sf21 cells were infected in monolayer cultures with a MOI of ten for 
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72 hours at 27 °C.  Cells were harvested and washed in PBS and cell pellets 
were flash frozen and stored at -80 °C.  All of the following procedures were 
performed at 4 °C in the presence of protease inhibitors (100 µg/ml AEBSF, 100 
µg/ml benzamidine, 30 µg/ml leupeptin, and 10 µg/ml pepstatin).  Cells were 
syringed and sonicated in cell homogenization buffer (PBS, 1 mM EDTA, 1 mM 
DTT, and 1 mM sodium azide) then centrifuged at 100,000 x g for 30 minutes to 
collect membranes.  Cell membranes were pre-extracted with 20 mM 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane-sulfonate (CHAPS; pH 12) for 30 
minutes followed by 20 mM PBS (pH 7.3), 0.5 M NaCl, 0.5 M urea, 0.5% Triton 
X-100, and 0.5 mM β-mercaptoethanol.  Cell residue was resuspended in 
extraction buffer (50 mM PBS (pH 8.0), 0.3 M NaCl, 10 mM imidazole, 0.2% 
Triton X-100, 1 mM β-mercaptoethanol, 1 mM sodium azide, and 2% Sarkosyl) 
for 20 minutes.  The extract was centrifuged at 100,000 x g for 1 hour and the 
supernatant collected and diluted 10 fold in extraction buffer lacking Sarkosyl.  
Recombinant full-length InsP3 receptor was solubilized from membranes as 
described (Mohler, Davis et al. 2005). Full-length protein expression was 
confirmed by SDS-PAGE/immunoblot on cell lysates using affinity-purified anti-
InsP3 receptor antibodies generated against the C-terminal of the InsP3 receptor 
(Mohler, Davis et al. 2004).  Equal quantities of cell lysate were added to binding 
reactions. 
 Yeast two-hybrid.  One round of transformation was performed to ensure 
that none of the plasmids induced autoactivation.  pACT2 DNA (0.05 µg) carrying 
the InsP3 receptor insert and 0.05 µg of pAS2-1 DNA carrying the ankyrin-B MBD 
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were co-transformed into AH109 yeast (using herring sperm DNA as a carrier) 
utilizing a standard lithium acetate protocol.  Co-transformed yeast were cultured 
at 30 °C on yeast peptone dextrose (YPD) media lacking leucine (-L), lacking 
tryptophan (-T), and lacking both leucine and tryptophan (-LT).  Colonies capable 
of growth on –LT media (referred to as double transformants) were further 
selected on media lacking adenine, histidine, leucine, and tryptophan (-AHLT).  
The positive control was a co-transformation of 0.05 µg TD1-1 and 0.05 µg pVA3 
and the negative control was a co-transformation of 0.05 µg TD1-1 and 0.05 µg 
pLAM5.  Transformants growing on –AHLT media following 3-5 days of 30 °C 
incubation were considered positive interactions. 
 In vitro transcription/translation and binding.  InsP3 receptor 
constructs were transcribed and translated using the TNT Coupled Reticulocyte 
Lysate System (Promega) with 20 µCi of Redivue L-[35S]-methionine (GE 
Healthcare) and 0.75 µg plasmid DNA.  Twenty micrograms of purified GST-
ankyrin-B MBD or purified GST were coupled to glutathione sepharose for two 
hours at 4 °C in binding buffer (50 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 
150 mM NaCl, 0.1% Triton X-100).  The beads were washed extensively in 
Buffer A (50 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 500 mM NaCl, 1% 
Triton X-100) and incubated with InsP3 receptor in vitro translated products 
representing InsP3 receptor amino acids 924-1582, 924-1550, 924-1454, 924-
1398, 924-1352, 924-1297, 924-1226, 924-1164, 924-1125, 924-991, 785-954, 
955-1143, and 2403-2575 or full-length InsP3 receptor products generated by 
baculoviral expression for four hours at 4 °C in binding buffer plus protease 
 134
inhibitor cocktail (Sigma).  Binding reactions were washed extensively in Buffer 
A, eluted, and analyzed by SDS-PAGE.  Radiolabelled proteins were detected by 
phosphorimaging.  Full-length InsP3 receptor products were detected by 
immunoblot with affinity purified anti-InsP3 receptor antibodies. 
 
Results 
Ankyrin-B interacts with the InsP3 receptor cytoplasmic N-terminal domain   
 Using a yeast two-hybrid approach to evaluate the interaction of ankyrin-B 
with InsP3 receptor, the ankyrin-B MBD was expressed as a fusion with the GAL4 
DNA-binding domain (“bait”).  Likewise, InsP3 receptor constructs were fused to 
the GAL4 activation domain (“prey”).  Due to the large size of the InsP3 receptor 
cytoplasmic N-terminus, this region was subdivided into seven fragments (Figure 
32A, B). 
 No interaction between the ankyrin-B MBD and an InsP3 receptor fusion 
protein containing the proposed ankyrin-binding site (Bourguignon and Jin 1995) 
at residues 2548-2558 was observed (Figure 32C, D).  Instead, ankyrin-B MBD 
interacted with InsP3 receptor fusion protein containing residues 924-1582 
(Figure 32C, D).  No interactions were detected between ankyrin-B MBD and 
InsP3 receptor fusion proteins using InsP3 receptor 1-346, 1-923, 347-923, 1581-
1931, 1581-2210, and 1932-2210 (Figure 32C, D).  These data demonstrate that 
a large N-terminal region of rat InsP3 receptor I contains the ankyrin-B binding 
motif.  Overall, these data demonstrate that the ankyrin-B binding region resides 
on the cytoplasmic, and not the lumenal, face of the InsP3 receptor. 
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Figure 32.  The ankyrin-B binding motif resides within amino acids 924-
1582 of the InsP3 receptor. 
 
(A)  Diagram of the InsP3 receptor monomer (da Fonseca, Morris et al. 2003).  
(B)  InsP3 receptor yeast two-hybrid constructs.  Fragments of the cytoplasmic 
regions of the InsP3 receptor monomer used in the initial assessment of the 
structural requirements of InsP3 receptor for interaction with ankyrin-B.  InsP3 
receptor construct 2543-2750 contains the previously predicted ankyrin-binding 
domain (Bourguignon and Jin 1995).  Constructs were designed based on 
identified structural folding boundaries defined by limited trypsin digestion 
(Yoshikawa, Iwasaki et al. 1999).  (C)  AH109 yeast cultures were co-
transformed with ankyrin-B MBD (bait) and a unique InsP3 receptor construct 
(prey).  Co-expression of bait and prey proteins was confirmed by inoculating 
onto –LT media.  Positive interactions were determined by growth on -AHLT 
media after five days incubation.  TD1-1 served as bait for both the positive and 
negative controls, while pVA3 and pLAM5 were used as prey for the positive and 
negative controls, respectively.  (D)  Summary data for ankyrin-B MBD/InsP3 
receptor construct interactions.  Reprinted with permission of Wiley-Liss, Inc. a 
subsidiary of John Wiley & Sons, Inc.  Kline, et al.  “Revisiting Ankyrin-InsP3 
Receptor Interactions:  Ankyrin-B Associates with the Cytoplasmic N-Terminus of 
the InsP3 Receptor.”  J Cell Biochem 104(4):1244-53 copyright 2008 by John 
Wiley & Sons, Inc. (Kline, et al. 2008). 
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Defining the minimal binding region on InsP3 receptor for ankyrin-B 
 Yeast two-hybrid.  Initial binding assays identified a domain within the N-
terminal region of the InsP3 receptor (residues 924-1582) that is required for 
ankyrin binding.  Due to the large size of the InsP3 receptor N-terminus, the 
ankyrin-binding region was further narrowed.  Using standard molecular biology 
techniques, additional InsP3 receptor prey plasmids based on residues 924-1582 
were created.  Ten additional mutants were engineered (Figure 33) and screened 
for interaction in yeast against the ankyrin-B MBD.  All ten InsP3 receptor 
truncated constructs bound to the ankyrin-B MBD (Figure 34A).  Even the 
smallest construct, corresponding to InsP3 receptor I residues 924-991 displayed 
significant ankyrin-B binding activity (Figure 34A). 
 Additionally, yeast two-hybrid analyses were performed with an InsP3 
receptor construct lacking residues 924-977 to determine whether these residues 
were necessary for the ankyrin-B/InsP3 receptor interaction (designated IP3R 
978-1582).  While co-expression of InsP3 receptor construct 978-1582 with 
ankyrin-B in AH109 cells was observed, there was no detectable binding of this 
GAL4-fusion protein with the ankyrin-B MBD (Figure 34B).  Therefore, these data 
demonstrate that InsP3 receptor residues within 924-991 are necessary, and 
sufficient, for interaction with ankyrin-B in the context of yeast. 
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Figure 33.  Identification of minimal requirements on InsP3 receptor for 
ankyrin binding. 
 
InsP3 receptor truncation constructs were generated to define the minimal 
structural requirements on InsP3 receptor for ankyrin binding.  Constructs 
represent truncations based on rat InsP3 receptor I residues 924-1582.  
Reprinted with permission of Wiley-Liss, Inc. a subsidiary of John Wiley & Sons, 
Inc.  Kline, et al.  “Revisiting Ankyrin-InsP3 Receptor Interactions:  Ankyrin-B 
Associates with the Cytoplasmic N-Terminus of the InsP3 Receptor.”  J Cell 
Biochem 104(4):1244-53 copyright 2008 by John Wiley & Sons, Inc. (Kline, et al. 
2008). 
 139
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34.  Defining the minimal ankyrin binding site on the InsP3 receptor 
N-terminus. 
 
(A)  Ankyrin-B MBD (bait) and a series of InsP3 receptor constructs (prey, Figure 
34) were co-transformed into AH109 yeast.  Positive interaction is seen with all 
constructs, with the smallest interacting region of the InsP3 receptor 
corresponding to amino acids 924-991.  Note that this region is located on the 
cytoplasmic N-terminus of the InsP3 receptor (refer to Figure 30).  (B)  InsP3 
receptor lacking residues 978-1582 (designated 978-1582) fails to interact with 
ankyrin-B MBD in yeast.  Yeast two-hybrid analysis with the 924-1582 prey 
construct was used as a positive control.  Reprinted with permission of Wiley-
Liss, Inc. a subsidiary of John Wiley & Sons, Inc.  Kline, et al.  “Revisiting 
Ankyrin-InsP3 Receptor Interactions:  Ankyrin-B Associates with the Cytoplasmic 
N-Terminus of the InsP3 Receptor.”  J Cell Biochem 104(4):1244-53 copyright 
2008 by John Wiley & Sons, Inc. (Kline, et al. 2008). 
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 In vitro binding analysis.  The yeast two-hybrid mapping data was 
confirmed using in vitro binding assays.  InsP3 receptor truncation constructs 
were subcloned into the pcDNA3.1(+) expression plasmid under the control of 
the T7 promotor for in vitro transcription/translation in the presence of 35[S]-
methionine.  The purified, radiolabelled translation products were incubated with 
GST alone or GST-ankyrin-B MBD.  Following incubation and extensive washing, 
bound radiolabelled InsP3 receptor products were eluted and analyzed by SDS-
PAGE and phosphorimaging.  Consistent with prior experiments performed in 
yeast, in vitro binding experiments demonstrated binding of all InsP3 receptor 
truncation constructs (including InsP3 receptor 924-991) (Figure 35A, B) with 
GST-ankyrin-B MBD.  No binding of control GST with any InsP3 receptor product 
was observed (Figure 35A, B). 
 To validate the binding results in the context of a full-length InsP3 receptor, 
baculoviral expression (in Sf21 cells) was used to generate full-length InsP3 
receptor and an InsP3 receptor mutant lacking residues 924-991 (InsP3 receptor 
∆924-991, Figure 36C).  Approximately equal amounts of InsP3 receptor proteins 
were incubated to immobilized GST or GST-ankyrin-B MBD.  Following extensive 
high salt washes, bound protein was eluted and analyzed by SDS-PAGE and 
immunoblot using affinity-purified InsP3 receptor Ig.  While association of wild 
type full-length InsP3 receptor with ankyrin-B MBD was observed, no association 
was detected between ankyrin and InsP3 receptor ∆924-991 (Figure 35C).  
Together, my binding data demonstrate that InsP3 receptor residues 924-991 are 
necessary and sufficient for ankyrin-B/InsP3 receptor interaction. 
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Figure 35.  InsP3 receptor residues 924-991 are required and sufficient for 
ankyrin-B association. 
 
(A)  Coomassie blue stained gel depicting purified GST and GST-ankyrin-B MBD.  
(B)  Representative in vitro binding reactions using radiolabeled InsP3 receptor 
constructs 924-991 and 924-1125.  Both constructs are able to associate with 
GST-ankyrin-B MBD.  (C)  Full-length InsP3 receptor and InsP3 receptor ∆924-
991 were incubated with GST-ankyrin-B MBD.  While full-length InsP3 receptor 
associates with ankyrin-B MBD, the InsP3 receptor lacking residues 924-991 
cannot.  Reprinted with permission of Wiley-Liss, Inc. a subsidiary of John Wiley 
& Sons, Inc.  Kline, et al.  “Revisiting Ankyrin-InsP3 Receptor Interactions:  
Ankyrin-B Associates with the Cytoplasmic N-Terminus of the InsP3 Receptor.”  J 
Cell Biochem 104(4):1244-53 copyright 2008 by John Wiley & Sons, Inc. (Kline, 
et al. 2008). 
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 To further narrow the ankyrin-binding domain of the InsP3 receptor, in vitro 
binding reactions were performed using GST-ankyrin-B MBD and in vitro 
translated products of each half of the identified ankyrin-binding domain.  
Specifically, InsP3 receptor products consisting of residues 785-954 (contains 
amino acids 924-954) and 955-1143 (contains amino acids 955-991) were 
generated (Figure 36A).  Larger polypeptides were used in order to incorporate 
more radiolabelled methionine residues and to increase peptide size for SDS-
PAGE analysis.  InsP3 receptor construct 955-1143 associated with ankyrin-B 
MBD (Figure 36B, C); whereas, InsP3 receptor residues 785-954 did not (Figure 
36B, C), suggesting that the ankyrin-binding region resides in amino acids 955-
991 of the InsP3 receptor.  Additionally, the InsP3 receptor C-terminal construct 
2403-2575, which contains a previously predicted ankyrin-binding motif, showed 
no detectable association with ankyrin-B (Figure 36B, C), consistent with my 
yeast two-hybrid data. 
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Figure 36.  Ankyrin-B associates with InsP3 receptor residues 955-991. 
   
(A)  Alignment of the ankyrin-B binding domain of the InsP3 receptor.  Note high 
sequence conservation in N- and C-terminal regions of the domain.  (B)  InsP3 
receptor ankyrin-binding domain (924-991) was split into two constructs and in 
vitro translated.  An InsP3 receptor C-terminal domain construct (residues 2403-
2575) containing the previously predicted ankyrin-binding domain was also in 
vitro translated.   While InsP3 receptor protein 955-1143 showed in vitro 
association with ankyrin-B MBD, InsP3 receptor proteins 785-954 and 2403-2575 
did not.  Reprinted with permission of Wiley-Liss, Inc. a subsidiary of John Wiley 
& Sons, Inc.  Kline, et al.  “Revisiting Ankyrin-InsP3 Receptor Interactions:  
Ankyrin-B Associates with the Cytoplasmic N-Terminus of the InsP3 Receptor.”  J 
Cell Biochem 104(4):1244-53 copyright 2008 by John Wiley & Sons, Inc. (Kline, 
et al. 2008). 
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Discussion 
 The current study was designed to evaluate the amino acid requirements 
on InsP3 receptor for ankyrin-B interaction.  Consistent with prior studies, I 
observed interaction between ankyrin-B and the InsP3 receptor (Bourguignon, 
Iida et al. 1993; Bourguignon, Jin et al. 1993; Feng and Kraus-Friedmann 1993; 
Joseph and Samanta 1993; Tuvia, Buhusi et al. 1999; Hayashi, Maurice et al. 
2000; Hayashi and Su 2001; Mohler, Schott et al. 2003; Mohler, Davis et al. 
2004; Mohler, Splawski et al. 2004; Mohler, Davis et al. 2005; Liu, Miyakawa et 
al. 2007).  However, my data establish that ankyrin interacts with the cytoplasmic 
and not the lumenal face of the InsP3 receptor.  Specifically, ankyrin-B interacts 
with the cytoplasmic N-terminal domain of the InsP3 receptor within residues 955-
991.  The new InsP3 receptor cytosolic ankyrin-binding region is consistent with 
an in vivo ankyrin/InsP3 receptor interaction.  These new results resolve the 
ability of these two proteins to interact in an in vivo cellular environment. 
 Ankyrins likely play multiple roles in normal InsP3 receptor function.  Based 
on work from multiple labs, ankyrin has a central role in the targeting of InsP3 
receptor to ER/SR membrane domains in both non-excitable and excitable 
tissues (Bourguignon, Iida et al. 1993; Bourguignon, Jin et al. 1993; Feng and 
Kraus-Friedmann 1993; Joseph and Samanta 1993; Tuvia, Buhusi et al. 1999; 
Hayashi, Maurice et al. 2000; Hayashi and Su 2001; Mohler, Schott et al. 2003; 
Mohler, Davis et al. 2004; Mohler, Splawski et al. 2004; Singleton and 
Bourguignon 2004; Mohler, Davis et al. 2005; Liu, Miyakawa et al. 2007).    
Moreover, ankyrin isoforms likely stabilize the receptor in close proximity with 
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effector and regulatory proteins (Lencesova, O'Neill et al. 2004; Mohler, Davis et 
al. 2005; Bhasin, Cunha et al. 2007; Liu, Miyakawa et al. 2007).    
 In summary, my new data identify the binding region on the ER/SR InsP3 
receptor for ankyrin-B.  Consistent with an in vivo association of cytosolic ankyrin 
with InsP3 receptor, my data demonstrate that ankyrin-B directly associates 
within amino acids 955-991 of the cytoplasmic N-terminal domain of InsP3 
receptor.   
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CHAPTER VII 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 My findings present evidence of a critical role for ankyrin-B in the targeting 
and regulation of two important channels in the excitable cell:  the KATP channel 
and the InsP3 receptor.  Specifically, I have presented data which demonstrate 
that ankyrin-B associates in vitro with Kir6.2, the pore-forming subunit of the KATP 
channel, and that this association is necessary for Kir6.2 targeting in vivo.  
Ankyrin-B+/- mice demonstrate significant hyperglycemia and isolated islets from 
ankyrin-B+/- mice exhibit a significant reduction in insulin secretion, suggesting 
that loss of ankyrin-B expression results in a diabetic phenotype.  Furthermore, I 
presented evidence that a known human mutation associated with PNDM, 
E322K, results in two distinct phenotypes:  loss of ankyrin-B-mediated Kir6.2 
targeting in vivo and a significant reduction in the ATP sensitivity of Kir6.2.  I also 
presented preliminary data supporting a role for ankyrin-B in the modulation of 
Kir6.2 ATP sensitivity.  These two phenotypes (a loss-of-function and a gain-of-
function, respectively) results in neonatal diabetes.  The ankyrin-B/Kir6.2 
association is a novel finding and suggests a possible target for therapeutic 
modulation of KATP channel activity.  Finally, my data demonstrates that ankyrin-B 
associates with the InsP3 receptor via a cytoplasmic N-terminal domain on the 
InsP3 receptor.  While numerous studies have demonstrated in vitro and in vivo 
interactions between ankyrin-B and the InsP3 receptor, there has been much 
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confusion about the validity of this interaction.  This confusion arose from a 
published study demonstrating that ankyrin-B associated in vitro with an 11 
amino acid motif in the C-terminal domain of the InsP3 receptor.   Structural 
studies later demonstrated that this motif resides in the lumen of the ER/SR and 
theoretically inaccessible to ankyrin-B.  My work conclusively demonstrates that 
this 11 amino acid motif is not the ankyrin-B-binding site in vivo and provides 
further evidence that the binding motif resides in the cytoplasmic N-terminus of 
the InsP3 receptor, nearly 2000 amino acids upstream of the originally reported 
site.   
 While my work has demonstrated a key role of ankyrins in ion channel 
targeting and biophysical regulation, I have found that with each single 
observation I have made over the last four years there were three or four new 
and more exciting questions to be asked.  In this chapter, I will focus on a 
number of promising future directions that I view as critical next steps for the 
field. 
 
Ankyrin Objectives 
 Ankyrin targeting and specificity.  While there is much circumstantial 
evidence to support a role for ankyrins in ion channel targeting and biophysical 
regulation, the precise nature of how ankyrin polypeptides are targeted remains a 
primary focus of research.  While a number of cell adhesion molecules (L1CAMs 
and CD44) (Kalomiris 1988; Ango 2004) and cytoskeletal elements (titin, tubulin, 
obscurin, and β-spectrin) (Kontrogianni-Konstantopoulos 2003; Davis 1984; 
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Bagnato 2003) have been implicated in the membrane localization of ankyrins, 
there are still questions regarding cell-type specific mechanisms associated with 
that targeting.  While cell adhesion molecules have been shown to target 
ankyrins in the central nervous system, it remains to be determined if these same 
molecules are required for ankyrin localization in other tissues.  Likewise, 
cytoskeletal elements have been implicated in the targeting of ankyrins in the 
cardiomyocyte and erythrocyte; however, the role of cytoskeletal elements in the 
targeting of ankyrins in other cell types has yet to be elucidated.  Along that same 
vein, identification of the intracellular trafficking systems (myosins, GTPases, 
GEFs, etc.) that are necessary for ankyrin targeting, as well as for ankyrin-
assisted targeting, are still a major focus of on-going research. 
 While ankyrins have been demonstrated to be necessary for proper ion 
channel localization, they have also been demonstrated to increase the stability 
of certain proteins at the plasma membrane (Cunha 2007; Mohler 2004).  
Whether this increased stability is a characteristic of all ankyrin-binding partners 
or whether the increased stability occurs in a cell-specific/ion channel-specific 
manner remain to be answered.  Ankyrins are reported to show cell-specific 
function; namely, association with distinct ion channels occurs in a cell-type 
specific manner.  Ankyrin-B, for example is responsible for the targeting of the 
NKA in cardiomyocytes (Mohler 2005); however, ankyrin-G targets the NKA in 
bronchial epithelial cells Kizhatil 2007), even though both cell types express 
ankyrin-B and ankyrin-G.  The focus of future studies is the determination of cell-
 149
specific pathways responsible for the cell-specific function of ankyrin 
polypeptides.  
KATP Channel and InsP3 Receptor Objectives 
 Further clarification of the ankyrin-B/Kir6.2 interaction.  While my data 
elucidate the ankyrin-B binding motif of Kir6.2, the region of ankyrin-B necessary 
for Kir6.2 interaction remains to be determined.  Likewise, the determination of 
half-life/stability of Kir6.2 and the KATP channel in the presence/absence of 
endogenous ankyrin-B could clarify a role for ankyrin-B in KATP channel 
expression at the plasma membrane.  Though many studies have demonstrated 
that Kir6.2 associates with SUR subunits, the nature of that association has not 
been clarified.  Future studies should focus on determining the definitive binding 
site on Kir6.2 for SUR subunits.  Determination of this site would provide vital 
insight into the mechanisms by which this channel is formed, trafficked, and 
regulated. 
 Role of ankyrin-B in the modulation of Kir6.2 ATP sensitivity.  While 
my preliminary data suggest a role for ankyrin-B in the regulation of KATP channel 
ATP sensitivity, further work must be performed to more clearly define this role.  
Specifically, the production of an endogenous peptide to compete association of 
ankyrin-B with Kir6.2 can be used not only to evaluate the effects on Kir6.2 
targeting and ATP sensitivity, but also to determine functional consequences of 
disrupting this association; namely, insulin secretion.  This can be performed 
either by transfection of the competing peptide into a cell line of insulin secretion 
(INS-1 cells, for instance) or generation of a mouse model expressing an 
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inducible (and beta cell-specific) competing peptide that disrupts the ankyrin-
B/Kir6.2 interaction.   
 The role of ankyrin-B in beta cell physiology and glucose 
homeostasis.  The effect of loss of ankyrin-B expression can be analyzed via 
the generation of an inducible beta cell-specific knock-out of ankyrin-B. 
Evaluation of glucose homeostasis in the ankyrin-B+/- mouse model is not without 
complications.  Since this model represents a global reduction in ankyrin-B, it 
would be difficult to draw conclusions as to the role of ankyrin-B in beta cell 
insulin secretion. The generation of a beta cell-specific knock-out of ankyrin-B 
would allow for the evaluation of ankyrin-B for beta cell activity, without the 
complicating factors associated with extrapancreatic tissues involved in glucose 
homeostasis, most of which also express ankyrin-B.  Also, it was surprising that 
no discernible differences in the expression of NKA and NCX were found in 
pancreatic lysates from ankyrin-B+/- mice.  Ankyrin-B+/- cardiac tissue 
demonstrates a significant decrease in the expression and localization of both 
NCX and NKA (Mohler, 2003), demonstrating a role for ankyrin-B in the targeting 
of these ion channels in cardiomyocytes.  As mentioned previously, ankyrin 
polypeptides demonstrate cell-specific activity with regard to the targeting of ion 
channels.  While ankyrin-B is responsible for the targeting of NKA in 
cardiomyocytes, ankyrin-G is required for the targeting of NKA in bronchial 
epithelial cells, even though both cells types express both ankyrin-B and ankyrin-
G.  Since pancreatic beta cells express both ankyrin-B and ankyrin-G, it would be 
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interesting to investigate the role of ankyrin-G in the targeting of NCX and NKA in 
pancreatic beta cells.  
 KATP channels also play critical roles in glucose homeostasis outside of the 
beta cell.  KATP channels in the skeletal muscle and adipose tissue are involved in 
insulin-stimulated glucose uptake.  KATP channels in ventromedial hypothalamic 
neurons mediate the counter-regulatory response to glucose (Miki, Liss et al. 
2001), while KATP channels in the arcuate nucleus are hypothesized to play a role 
in appetite regulation (Wang, Liu et al. 2004).  It will be interesting to determine 
whether ankyrin-B-based pathways for KATP channel targeting and metabolic 
regulation exists within these cells types. 
 Ankyrin-B and role of the cytoskeleton in KATP channel modulation.  
While numerous studies have demonstrated a definitive role of the cytoskeleton 
in Kir6.2 metabolic regulation (outlined in Chapter III) (Brady, Alekseev et al. 
1996; Furukawa, Yamane et al. 1996; Terzic and Kurachi 1996; Yokoshiki, 
Katsube et al. 1997), my results suggest that the association with ankyrin-B, as a 
linker between Kir6.2 and the cytoskeleton, may resolve underlying questions 
regarding those previously-published observations.  Specifically, the use of a 
competing peptide to remove ankyrin-B association from the actin-spectrin 
cytoskeleton, while still maintaining the ankyrin-B/Kir6.2 association, could be 
critical in confirming that hypothesis.   
 Ankyrin-B modulation of the Kir6.2/SUR association.  Further studies 
regarding the role of ankyrin-B in the regulation of SUR/Kir6.2 association are 
also warranted.  Many studies have demonstrated a loss of sulfonylurea-induced 
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KATP channel closure in the presence of cytoskeletal disrupting drugs (Terzic and 
Kurachi 1996).  Ankyrin-B may play a role in either the sensitivity of SUR 
subunits for sulfonylurea action or may be involved in the transduction of 
sulfonylurea binding to the SUR subunit to conformational changes in the Kir6.2 
pore.  Considering the reports demonstrating a correction of SUR trafficking 
defects following the administration of sulfonylureas (Yan 2004), future work with 
regard to ankyrin-B and SUR subunits is also vital in understanding the role of 
ankyrin-B in KATP channel targeting and modulation.  
 The role of ankyrin-B in the targeting of KATP channels to non-insulin 
containing granules.  While KATP channel expression at the beta cell plasma 
membrane is critical for stimulus-secretion coupling, much published data 
demonstrate that the majority of KATP channel expression is on non-insulin 
containing granules (Yang and Wenna et al. 2007).  While the role of those 
channels has yet to be determined, it is of interest to evaluate whether ankyrin-B 
is also involved in the targeting and metabolic regulation of granule KATP 
channels as well.  Knock-down of ankyrin-B expression in a cell model of insulin 
secretion, like the INS-1 cell line, could be used to determine the effect on both 
plasma membrane and granule KATP channel expression, as well as evaluation of 
the functional effects of loss of ankyrin-B; namely, insulin secretion.   
 The role of ankyrin-B in beta cell PP2A targeting.  Protein 
phosphorylation has been demonstrated to play a vital role in insulin secretion.  
The overall state of protein phosphorylation is a function of both the 
phosphorylation by various kinases and the dephosphorylation by protein 
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phosphatases.  Therefore, net phosphorylation levels can be elevated by either 
activation of protein kinases or inhibition of protein phosphatases.  Recent work 
has established a role for ankyrin-B in the targeting of the protein phosphatase 
PP2A in heart via association with the B56α subunit of PP2A (Bhasin 2007).  
PP2A has been shown to play a vital role in beta cell physiology via its regulation 
of insulin secretion.  Specifically, inhibition of PP2A by okadaic acid results in 
almost complete suppression of insulin secretion (Krautheim 1999), as well as 
reduced stimulation of acetyl-CoA carboxylase (Kowluru 2001).  Acetyl Co-A 
carboxylase catalyzes the formation of malonyl-CoA, a precursor in the 
biosynthesis of long-chain fatty acids, which have been implicated in insulin 
secretion.  Future work focusing on the role of ankyrin-B in the phosphorylation 
status of critical beta cell proteins, via the formation of macromolecular signaling 
complexes, will be critical in determining the function of ankyrin-B in the 
macromolecular complexes necessary for efficient beta cell function. 
 The effect of human ankyrin-B mutations on KATP channel targeting 
and regulation:  A number of human ankyrin-B mutations have been identified 
which result in a loss of ankyrin-B-dependent targeting of a number of ion 
channels (Lehnart 2007).  Clinical evaluation of these individuals with regard to 
glucose homeostasis need to be performed, as well as in vivo and in vitro work to 
determine the role of these mutations in the targeting/regulation of KATP channel 
activity, as well as KATP channel stability.  This is of clinical relevance to 
individuals who have been identified as carriers of these mutations, so that 
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appropriate therapeutic measures can be implemented early, specifically, in 
regard to lifestyle changes and the administration of anti-diabetic medication. 
 InsP3 receptor expression in the pancreatic beta cell.  While the KATP 
channel represents a critical regulator of insulin secretion, it is not the only 
ankyrin-B binding partner present in the pancreatic beta cell.  The role of ankyrin-
B in the targeting and regulation of the InsP3 receptor in the pancreatic beta cell 
has not been evaluated.  Activation of muscarinic receptors on the beta cell 
results in release of Ca2+ from the ER, via the activation of PLC and the 
generation of InsP3.  The InsP3 receptor-mediated pathway for insulin secretion 
can bypass the KATP-dependent glucose-stimulated pathway and stimulate insulin 
secretion in response to acetylcholine, GLP-1, and gastric inhibitory peptide 
(GIP).  Considering that some of the pharmacological agents used to treat type 2 
diabetes are GLP-1 mimetics (exenatide/Byetta™) (Heine 2005) or inhibitors of 
the breakdown of endogenous GLP-1 and/or GIP (vildagliptin/Galvus™ and 
sitagliptin/Januvia™) (Herman 2005; Ahren 2004), further evaluation of the role 
of the InsP3 receptors in beta cell physiology is an important focus for future 
work. 
 Ankyrin-B in extrapancreatic KATP channel function.  The KATP channel 
is a critical component in the physiology of cardiomyocytes and neurons, 
providing cytoprotective functions as well as coordination of electrical activity.  I 
have generated preliminary data demonstrating that ankyrin-B and Kir6.2 co-
immunoprecipitate from rat pancreatic heart lysate (Figure 14), suggesting that 
ankyrin-B may be involved in the targeting and/or regulation of Kir6.2 in cardiac 
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tissue.   Evaluation for defects in action potential duration, as well as defects in 
ischemic preconditioning, in ankyrin-B+/- mice would be a critical first step in the 
evaluation of ankyrin-B-dependent pathways for KATP channel targeting and 
function in cardiomyocytes.  
 Further definition of the ankyrin-B-binding region of the InsP3 
receptor.  All three major InsP3 receptor isoforms associate with ankyrin-B 
(Mohler, Davis et al. 2004).  Furthermore, the expression of the three InsP3 
receptor isoforms is reduced in tissues derived from ankyrin-B+/- or ankyrin-B null 
mice (Mohler, Davis et al. 2004).  Therefore, the precise binding site on the InsP3 
receptor is likely a conserved motif within the receptor subtypes (Figure 36A).  
While a previous study proposed that ankyrin directly associated with InsP3 
receptor at a site based on limited sequence similarity to an ankyrin-binding 
region of CD44 (Bourguignon and Jin 1995), it is now clear that most ankyrin-
binding proteins do not have conserved sequence binding motifs.  Instead, 
ankyrin-binding proteins associate with unstructured and non-conserved protein 
motifs (reviewed in (Bennett and Baines 2001)).  Our group previously identified 
a series of positively-charged residues on the ankyrin-B membrane-binding 
domain that are essential for InsP3 receptor binding.  Based on these data, we 
predict that ankyrin-B will interact with a conserved, and likely negatively-
charged, site within the 955-991 region of the InsP3 receptor.  Future goals will 
be to further refine the binding site for ankyrin and to analyze the cellular 
targeting of an InsP3 receptor that lacks ankyrin-binding.  Unfortunately, due to 
the homo- and hetero-trimeric organization of the InsP3 receptor protein complex, 
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these experiments will not likely be straightforward. Additionally, using current 
viral technologies, it is difficult to express full-length InsP3 receptor mutants in 
primary cells.    
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